| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Microbot Medical Inc.$1.89
+0.05 (+2.69%)
F 16Pipeline Score MedTech · Commercial
Market Cap
114.85 M
EPS
-0.28
P/E Ratio
-
Value Trade
2.35 M
SEC Financials
Q1 2026Dilution Risk
Revenue
105.00 K
R&D Expenses
1.29 M
Operating CF
-5.05 M
Total Assets
78.07 M
Total Liabilities
3.96 M
Equity
74.11 M
D/E Ratio
12,345
-8.06 %
Week
-21.56 %
1 Month
-19.72 %
3 Month
-2.29 %
6 Month
-76.41 %
5 Year
-100 %
All Time
Cash Data
Cash Position
72.50 M
Monthly Burn
1.68 M
Runway
41.4 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
364.32 K
52 Week Range
1.60 - 4.67
% held by Insiders
9.14 %
% held by Institutions
21.5 %
Enterprise Value
42.24 M
Total Shares
67.17 M
Short %
11.3 %
Float Shares
65.02 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Microbot Medical Inc.
4Total events
2Upcoming
1Tier-1 (high impact)
2026 – 2026Coverage
Upcoming catalysts 2
Drug Pipeline Intelligence
F16
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 13%
Micro Cap (rank 794 of 911)
Percentile RankMicrobot Medical Inc. has significant pipeline risk (16/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
LIBERTY Endovascular Robotic System | — | — | 2025-04-09 | 100% success in robotic navigation; 92% reduction in radiation exposure; no adverse events reported Read More | Microbot Medical Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY Endovascular Robotic System Successful robotic navigation was achieved in every case and met the Read More | |
LIBERTY Endovascular Robotic System | — | — | 2025-04-09 | 100% success in robotic navigation; 92% reduction in radiation exposure; no adverse events reported Read More | Microbot Medical Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY Endovascular Robotic System Successful robotic navigation was achieved in every case and met the Read More | |
LIBERTY Endovascular Robotic System | — | — | 2025-04-09 | 100% success in robotic navigation; 92% reduction in radiation exposure; no adverse events reported Read More | Microbot Medical Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY Endovascular Robotic System Successful robotic navigation was achieved in every case and met the Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MBOT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MBOT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MBOT▲ +2.7%today
Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026
Microbot Medical Inc. reported over 100% growth in revenue and customer acquisition for Q2 2026, driven by the Full Market Release of its LIBERTY System. The company is expanding its U.S. sales territories and has received marketing clearance from Israel. Increased procedure volumes were noted among health systems that adopted the system, indicating rising demand.
Read more →MBOTMicrobot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader
Microbot Medical has signed a Letter of Agreement with Sanmina Corporation to enhance manufacturing capacity for its LIBERTY Endovascular Robotic System. This partnership aims to support the growing demand in the U.S. and international markets, including recent clearances in Israel. The agreement is expected to improve operational efficiencies and reduce costs as Microbot scales production.
Read more →MBOTMicrobot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System
Microbot Medical Inc. has been awarded the Innovative Start-Up Award by Surgical Robotics Technology for its LIBERTY Endovascular Robotic System. This system is the only FDA-cleared, single-use, remotely operated robotic solution for peripheral endovascular procedures. The award highlights the system's potential to transform healthcare and its growing adoption in leading medical centers.
Read more →MBOTMicrobot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System
Microbot Medical Inc. has announced that a prominent academic center in Pennsylvania is the first in the state to adopt its LIBERTY Endovascular Robotic System. This adoption marks a significant expansion of the company's presence in the Northeast U.S., joining other health systems in New York City and Boston. The company plans to extend its sales efforts to the West Coast and is also focusing on federal healthcare systems.
Read more →MBOTMicrobot Medical® Enters Into an Agreement to Expand Access for America’s Veteran and Military Patient Populations
Microbot Medical has partnered with Lovell Government Services to enhance access to its LIBERTY Endovascular Robotic System for U.S. veterans and military patients. This collaboration aims to streamline procurement through federal contracting systems, facilitating the availability of advanced medical technologies. The LIBERTY System will be included in Lovell's Federal Supply Schedule, expected to activate in Q3 2026.
Read more →MBOTMicrobot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic System
Microbot Medical Inc. has announced that a leading healthcare system in Michigan is the first in the state to adopt its LIBERTY Endovascular Robotic System. This follows a recent expansion into North Carolina and reflects a growing demand for robotic solutions in vascular care. The LIBERTY System, which is FDA-cleared, aims to enhance procedural workflows and reduce radiation exposure.
Read more →MBOTMicrobot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic System
Microbot Medical Inc. has successfully secured its first healthcare system customer in North Carolina for its LIBERTY Endovascular Robotic System. This marks a significant milestone as the company expands its geographic reach, adding to its growing list of health system adopters. CEO Harel Gadot expressed optimism about the company's commercial strategy and future market penetration.
Read more →MBOT▲ +5.8%on this news· ran to +19% by day 3
Microbot Medical Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY Endovascular Robotic System Israel becomes the second jurisdiction and the first outside of the U.S. to grant
Microbot Medical has achieved a significant regulatory milestone with Israel granting marketing clearance for its LIBERTY Endovascular Robotic System. This marks Israel as the first country outside the U.S. to approve the system, facilitating commercialization efforts. The approval will allow the company to obtain a Free Sale Certificate for market submissions in other regions. Microbot is also working towards CE Mark certification, aiming to expand its commercial activities into the EU market by the end of 2026.
Read more →MBOTMicrobot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary Bercu
Microbot Medical Inc. is set to hold an analysts and investors conference call on May 18th, focusing on recent progress with its LIBERTY Endovascular Robotic System. During the call, company executives will address claims made in a recent third-party article and clarify misrepresentations. Expert users of the system, Dr. Charles Briggs and Dr. Zachary Bercu, will join to share their experiences with the LIBERTY System, contributing to a discussion aimed at keeping investors accurately informed.
Read more →MBOT▼ -14.7%on this newsshared move
Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026 Recent transition to the Full Market Release has already
Microbot Medical Inc. has transitioned to commercial operations, achieving revenue from its limited market release of the LIBERTY Endovascular Robotic System in Q1 of 2026. The company recently initiated a full market release, which has already resulted in revenue exceeding that of the first quarter. Adoption of the LIBERTY System is accelerating, with hospitals across six states adopting the technology and customer orders increasing. Additionally, the company anticipates further growth supported by new industry guidelines and participation in major medical conferences.
Read more →MBOT▼ -14.7%on this newsshared move
Microbot to Hold Conference Call to Review Recent Progress; Executive Team to be Joined by Current LIBERTY Users, Dr. Charles Briggs and Dr. Zachary Bercu Conference call and live webcast to be held Monday, May 18 th at
Microbot Medical Inc. (NASDAQ: MBOT) will hold a conference call on May 18th to review the recent progress of the LIBERTY Endovascular Robotic System. The call aims to address inaccuracies made in an unaffiliated third-party article, ensuring the investing public is well-informed. Dr. Charles Briggs and Dr. Zachary Bercu, both users of the LIBERTY System, will share their experiences during the call. This initiative is part of Microbot's efforts to clarify any misleading statements and reinforce its commitment to innovation in endovascular care.
Read more →MBOTMicrobot Medical 's LIBERTY Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites Commercial adoption of the LIBERTY System by sites
Microbot Medical's LIBERTY Endovascular Robotic System has gained adoption by multiple accounts, including sites that participated in the ACCESS-PVI pivotal clinical trial, indicating a strong validation of the system's value in clinical settings. The company's ongoing commercial efforts are bolstered by a recent full market release and interest from hospital executives at major medical conferences. Additionally, the upcoming Global Embolization Symposium & Technologies (GEST) conference will provide a platform to further showcase LIBERTY to a broad audience of interventional specialists. However, the company faces challenges related to regulatory approvals and market conditions that could influence future growth.
Read more →MBOTMicrobot Medical Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA) Commencement of activities in international m
Microbot Medical Inc. has appointed Alon Tamir as Vice President of Sales for Europe, the Middle East, and Asia to strengthen its commercial readiness in international markets. The company aims to leverage its FDA-cleared LIBERTY Endovascular Robotic System, expecting CE mark approval by the end of 2026. With the EMEA region presenting substantial growth potential, Microbot seeks to implement a comprehensive sales strategy that enables expansion while maintaining its focus on the U.S. market. The recent successful full market release in the U.S. underscores confidence in the system's adoption and the company's growth strategy.
Read more →MBOTMicrobot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®
Microbot Medical Inc. has welcomed updated occupational protection guidelines from leading medical societies, including SIR and CIRSE. These guidelines aim to lower radiation exposure and improve ergonomic conditions for healthcare practitioners involved in interventional radiology. The LIBERTY System is positioned as a solution to enhance safety and efficiency in these procedures. The endorsement from multiple societies highlights the growing emphasis on protecting healthcare providers.
Read more →MBOTMicrobot Medical® to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference
Microbot Medical Inc. will present its recent commercial achievements and the Full Market Release of the LIBERTY Endovascular Robotic System at the Needham Virtual Healthcare Conference. CEO Harel Gadot will discuss the company's strategic positioning and growth opportunities. The LIBERTY system is notable for being the first FDA cleared, single-use robotic system designed to enhance precision in endovascular procedures.
Read more →MBOT▼ -9.3%on this newsshared move
Microbot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific Meeting
Microbot Medical Inc. has announced the commencement of its full market release of the LIBERTY Endovascular Robotic System at the Society of Interventional Radiology Annual Scientific Meeting. The system has been adopted by several prominent healthcare systems and is recognized for its precision and efficiency in various procedures. The company aims to expand its sales footprint significantly by the end of 2026.
Read more →MBOTEmory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®’s LIBERTY® Endovascular Robotic System
Emory Healthcare has successfully utilized Microbot Medical's LIBERTY Endovascular Robotic System for robotic peripheral endovascular procedures, including the first robotic prostate artery embolization for benign prostatic hyperplasia and Y-90 radioembolization mapping for liver cancer. This innovative system aims to improve patient access to high-quality care and enhance procedural efficiency. The LIBERTY System is the only FDA-cleared, single-use, remotely operated robotic system for such procedures.
Read more →MBOTMicrobot Medical® Strengthens LIBERTY® Endovascular Robotic System Position with Publication of its ACCESS PVI Pivotal Study in Leading Peer-Reviewed Medical Journal
Microbot Medical announced the publication of its ACCESS PVI pivotal study in the Journal of Vascular and Interventional Radiology, highlighting the quality of the research. The study supports the LIBERTY Endovascular Robotic System, which received FDA clearance in September 2025. The company aims to expand clinical evidence to enhance market adoption of this innovative technology.
Read more →MBOTMicrobot Medical® to Participate at the 38th Annual Roth Conference
Microbot Medical Inc. will participate in the Roth Annual Growth Conference from March 22-24, 2026. CEO Harel Gadot will present the company's achievements and the LIBERTY Endovascular Robotic System, which addresses healthcare needs. The conference aims to showcase the company's growth story and facilitate meetings with investors. A full market release of LIBERTY is planned for April 2026.
Read more →MBOTMicrobot Medical to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time Live Webcast on Thursday, March 19 at 8:40 am ET to Highlight the Expanding Clinical Experience w
Microbot Medical Inc. (NASDAQ: MBOT) will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, marking its first invitation to the event. CEO Harel Gadot will highlight recent achievements of the LIBERTY Endovascular Robotic System and discuss key market growth drivers during a live presentation on March 19, 2026. The company's limited market release of the LIBERTY system has sparked interest from leading healthcare institutions, suggesting a positive trend in adoption and potential for future growth.
Read more →MBOTMicrobot Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals from Ionizing Radiation
Microbot Medical Inc. supports the AMA's new policy aimed at enhancing protections for healthcare professionals against ionizing radiation. The company's LIBERTY Endovascular Robotic System offers a solution by allowing remote operation, which significantly reduces radiation exposure during procedures. With an upcoming full market release planned for April 2026, Microbot aims to address staffing shortages and improve safety in endovascular care.
Read more →MBOTMicrobot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event
Microbot Medical Inc. has confirmed operational stability amid current geopolitical tensions, ensuring that its U.S. and Israeli operations remain unaffected. The company is focused on the U.S. market following the FDA clearance of its LIBERTY Endovascular Robotic System, which is set for a full market release at the upcoming Society of Interventional Radiology conference. To support this expansion, Microbot is enhancing its commercial team and inventory levels.
Read more →MBOT▲ +23.9%on this news
Tampa General Hospital is the First Health System in Florida to Adopt the LIBERTY® Endovascular Robotic System
Microbot Medical Inc. announced that Tampa General Hospital has become the first health system in Florida to adopt its LIBERTY® Endovascular Robotic System. This adoption follows the recent FDA 510(k) clearance and signifies a growing readiness for advanced robotic solutions in peripheral endovascular procedures. The system aims to improve patient care while addressing physician safety concerns.
Read more →MBOTMicrobot Medical 's LIBERTY Endovascular Robotic System Continues to Expand Market Visibility; Being Featured at an Industry Leading Innovation Conference Global Robotic Leaders Convene to Discuss & Highlight Surgical Ad
Microbot Medical Inc. announced that its LIBERTY Endovascular Robotic System will be featured at the Surgical Disruptive Technology Summit during the SAGES NBT Innovation Weekend in Houston. CEO Harel Gadot will discuss the advantages of the LIBERTY System and its role in advancing minimally invasive surgical practices. The system aims to enhance precision and reduce radiation exposure in vascular procedures, showcasing its potential for broader adoption and improved patient care.
Read more →MBOTMicrobot Medical®’s LIBERTY® Endovascular Robotic System Highlighted at a Leading Vascular Disease Management Conference
Microbot Medical's LIBERTY Endovascular Robotic System was prominently featured at the International Symposium on Endovascular Therapy (ISET) in Miami Beach. The discussions emphasized its innovative role and potential in advancing endovascular procedures. The system, which is FDA cleared and designed for single-use, aims to enhance precision while reducing radiation exposure. The company plans a full market release at the Society of Interventional Radiology conference in April 2026.
Read more →MBOT▼ -6.9%on this news· ran to +18% by day 3
Microbot Medical® to Leverage Current Users Experience of the LIBERTY® Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption
Microbot Medical Inc. is participating in the Society of Interventional Oncology annual meeting to promote its LIBERTY Endovascular Robotic System. The conference allows the company to share user experiences and conduct live demonstrations, aiming to boost commercial adoption. The LIBERTY system is set for full market release in April 2026, following its limited release in late 2025.
Read more →MBOTMicrobot Medical Continues its 2025 Momentum; Announces Key 2026 Milestones
Microbot Medical Inc. is experiencing strong momentum as it enters 2026, following a successful limited market release of its LIBERTY® Endovascular Robotic System. The company achieved FDA 510(k) clearance and is preparing for a full market release in Q2 2026. Positive customer feedback and a targeted market of 2.5 million procedures annually position Microbot for significant growth.
Read more →MBOT▲ +21.8%on this news
Microbot Medical® Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY® Endovascular Robotic System
Microbot Medical Inc. has announced that Emory University Hospital is the first in the world to adopt its LIBERTY Endovascular Robotic System. This system, which is FDA cleared, aims to improve patient care in peripheral endovascular procedures. The collaboration will also establish an Endovascular Robotics Program at Emory, further advancing the field of interventional radiology.
Read more →MBOTMicrobot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.
Microbot Medical Inc. has commenced the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S., following FDA clearance. The release targets areas with high procedure volumes and aims to gather real-world insights from early adopters. The company plans a full market launch at the Society of Interventional Radiology meeting in April 2026.
Read more →MBOTMicrobot Medical® to Commercially Debut the LIBERTY® System at The Symposium on Clinical Interventional Oncology Annual Meeting
Microbot Medical Inc. will showcase its LIBERTY® Endovascular Robotic System at the Symposium on Clinical Interventional Oncology in Miami from October 17-19. This marks the company's first commercial exhibition following FDA clearance. The firm has also finalized its commercial leadership team to support the upcoming limited market launch planned for Q4 2025.
Read more →MBOTMicrobot Medical® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic System
Microbot Medical Inc. has secured a U.S. logistics partner to aid in the commercialization of its LIBERTY® Endovascular Robotic System, which is FDA-cleared. The limited market release is set for Q4 2025, with a broader launch planned for April 2026 during a major conference. The partnership aims to enhance inventory management and customer support.
Read more →MBOTMicrobot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
Microbot Medical Inc. has completed the final closing of its exercise of preferred investment options, raising approximately $25.2 million in gross proceeds. The offering, which occurred in three tranches, allows the company to issue new short-term preferred investment options. The funds will support the development and commercialization of the LIBERTY® Robotic System and other corporate purposes. However, there are risks associated with the exercise of these options and market conditions.
Read more →MBOTMicrobot Medical® Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio
Microbot Medical has been granted its first patent in Japan for its LIBERTY® Endovascular Robotic System, expanding its global intellectual property portfolio. The company has also received patents in the U.S., China, and Israel in the last 90 days. Following FDA clearance, Microbot is focusing on commercializing the LIBERTY System in the U.S. while exploring opportunities in other global markets.
Read more →MBOT▲ +5.1%on this news
Miocrbot Medical® CEO to Discuss Recent FDA Clearance of the LIBERTY® Endovascular Robotic System
Microbot Medical Inc. has announced that its CEO, Harel Gadot, will be interviewed on Benzinga All Access to discuss the recent FDA clearance of the LIBERTY® Endovascular Robotic System. The system, which received FDA 510(k) clearance on September 8, 2025, aims to redefine the peripheral endovascular space. The interview is scheduled for September 24, 2025.
Read more →MBOT▲ +5.1%on this newsshared move
Microbot Medical CEO to Discuss Recent FDA Clearance of the LIBERTY Endovascular Robotic System Livestream Interview Can be Viewed on September 24th at 10:45am ET at Benzinga All Access Live
Microbot Medical Inc. has announced that its CEO, Harel Gadot, will participate in a livestream interview to discuss the recent FDA clearance of their LIBERTY Endovascular Robotic System. The interview is scheduled for September 24th at 10:45am ET on Benzinga All Access Live. The LIBERTY system represents a significant advancement in endovascular care as the first single-use, remotely operated robotic solution aimed at improving precision and provider safety in procedures. The company is preparing for commercialization in the U.S. market.
Read more →MBOTMicrobot Medical Announces First Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
Microbot Medical has announced the first closing of its preferred investment options, raising approximately $25.2 million. A second closing is anticipated by October 15, 2025, which may bring in an additional $4 million. If fully exercised, the preferred options could yield potential gross proceeds of around $63 million. The funds will be used to support the development, commercialization, and regulatory activities of the LIBERTY® Robotic System, as well as for general corporate purposes. However, the company faces uncertainties regarding the exercise of the options and market conditions.
Read more →MBOT▼ -15.6%on this newsshared move
Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for Up to $92.2 Million in Gross Proceeds
Microbot Medical Inc. has announced agreements for the exercise of preferred investment options, potentially raising up to $92.2 million. The offering will occur in two closings, with the first expected on September 16, 2025. Proceeds will be used for the development of the LIBERTY® Robotic System and other corporate purposes. The company has engaged H.C. Wainwright & Co. as the exclusive placement agent.
Read more →MBOT▼ -14.4%on this news
REMINDER: Microbot Medical to Highlight FDA 510(k) Clearance of the LIBERTY Endovascular Robotic System at the H.C. Wainwright Annual Investor Conference
Microbot Medical Inc. announced that CEO Harel Gadot will present the FDA clearance of the LIBERTY Endovascular Robotic System at the H.C. Wainwright Annual Investor Conference. This system is notable for being the first single-use, remotely operated robotic solution for peripheral endovascular procedures. The presentation is scheduled for September 9 at 9:00 am ET.
Read more →MBOT▼ -14.4%on this newsshared move
Microbot Medical Receives FDA 510(k) Clearance for Its LIBERTY Endovascular Robotic System Accelerated Launch Readiness Plans Position Company for Commercialization during Q4 2025 The Company's Initial Addressable Market
Microbot Medical Inc. has received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, marking a significant advancement in endovascular robotics. The company plans to launch the LIBERTY System commercially in Q4 2025, targeting approximately 2.5 million annual peripheral endovascular procedures in the U.S. Clinical studies have shown promising results, including high navigation success and reduced radiation exposure for practitioners. The announcement positions Microbot Medical to capitalize on market opportunities and enhance the quality of care in medical procedures.
Read more →MBOT▲ +7.1%on this news· ran to +35% by day 3
Microbot Medical Granted U.S. Patent that Significantly Expands Potential Market Applications With the Newly Granted IP, the Company's IP Portfolio for the LIBERTY System now includes 12 patents granted globally and 57 p
Microbot Medical Inc. announced the granting of a significant U.S. patent for its LIBERTY Endovascular Robotic System, expanding its potential market applications. The patent allows for a modular design that can address a wider array of endovascular procedures, potentially increasing the company's market reach. With this, the company's patent portfolio now consists of 12 granted patents globally and 57 pending applications. Despite these advancements, the LIBERTY system is currently an investigational device and awaits FDA clearance for market availability.
Read more →MBOT▲ +8.7%on this news
Microbot Medical Receives Non-Dilutive Grant to Enhance Operational Capabilities Strengthens Balance Sheet and Continues Commercialization Readiness Plans for the LIBERTY System as it Nears FDA Marketing Clearance Decisi
Microbot Medical Inc. has been awarded a non-dilutive grant of NIS 2.15 Million (approximately $630,000) from the Israel Innovation Authority. This funding will enhance the company's operational capabilities and support the commercialization of its LIBERTY Endovascular Robotic System, which is currently awaiting FDA marketing clearance. The IIA's decision recognizes the company's achievements and the market potential for its innovative robotic system. The grant is seen as a validation of Microbot's technology and reflects the IIA's confidence in the company's ability to scale manufacturing effectively.
Read more →MBOTE xhibit 99.1 Microbot Medical Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales Company Continues to Strengthen Organizational Infrastructure with Success-Driven Medical Device Veteran HI
Microbot Medical Inc. (NASDAQ: MBOT) announced the appointment of Christina Bailey as its new Vice President of Sales, aiming to strengthen its commercial leadership. With over 20 years of experience in medical device sales and successful track record from companies like Boston Scientific and Abbott, Bailey is poised to lead efforts in launching the LIBERTY Endovascular Robotic System. This innovative system is currently awaiting FDA clearance, which presents some regulatory uncertainties for the company. Her addition to the team is expected to enhance sales strategies and operational growth.
Read more →MBOTMicrobot Medical Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales
Microbot Medical has appointed Christina Bailey as its new Vice President of Sales. With a robust background in the medical device industry and experience as a two-time U.S. Olympian, Bailey is expected to drive the sales team and support the anticipated launch of the LIBERTY Endovascular Robotic System. This strategic move aims to strengthen the company's commercial operations and sales initiatives. Bailey's previous roles include leadership positions at major medical companies, equipping her with relevant insights for industry growth.
Read more →MBOTMicrobot Medical to Open Inaugural Endovascular Robotics Session at the Society of Robotic Surgery Annual Meeting Leading Endovascular Innovators to Highlight Emergence and Growth of Robotics in the Specialty
Microbot Medical Inc. will take part in the inaugural Endovascular Robotics session at the Society of Robotic Surgery annual meeting, occurring from July 16-20, 2025, in Strasbourg, France. The session, aimed at highlighting the emerging role of robotics in endovascular procedures, will include a discussion led by medical experts. The company's LIBERTY Endovascular Robotic System aims to revolutionize robotic surgery, although it currently awaits FDA 510(k) clearance for commercial use in the U.S.
Read more →MBOTMicrobot Medical Added to the Russell Microcap Index Automatic inclusion in the appropriate growth and value style indexes
Microbot Medical Inc. has been added to the Russell Microcap Index, effective immediately. This inclusion is seen as a significant milestone, indicating strong execution and momentum within the company, especially as it prepares for the anticipated Q3 launch of its LIBERTY Endovascular Robotic System. This recognition enhances the company's visibility at a crucial time as it continues interactions with the FDA regarding its device. Membership in the index allows for automatic inclusion in additional growth and value style indexes, indicating potential for increased investor interest.
Read more →MBOTMicrobot Medical Strengthens Global IP Portfolio with Newly Granted Patent in China Significant Development Supports Long-Term Global Commercial Strategy of the LIBERTY System
Microbot Medical Inc. announced the granting of a crucial patent in China, bolstering its global intellectual property portfolio and supporting its commercialization strategy for the LIBERTY Endovascular Robotic System. This development aligns with the company's plans for a U.S. launch in Q3 2025, pending FDA clearance. As the company aims to enhance patient care and procedural capabilities, it highlights its commitment to expand into international markets. However, risks related to regulatory approvals and market conditions remain prevalent as the company progresses.
Read more →MBOT▼ -11.4%on this news
Microbot Medical Continues to Strengthen Commercial Capabilities in Preparation for the anticipated Q3 2025 Launch of its LIBERTY Endovascular Robotic System The addition of the head of Sales Operations & Analytics aims
Microbot Medical Inc. (NASDAQ: MBOT) has announced the strengthening of its commercial team in preparation for the anticipated launch of its LIBERTY Endovascular Robotic System, expected in Q3 2025. The recent hiring of the head of Sales Operations & Analytics aims to enhance sales infrastructure and execution. Productive dialogues with the FDA are ongoing, and the company anticipates receiving a 510(k) decision within this year's third quarter, which aligns with its planned launch timeline. However, the system is currently under FDA review, and clearance for commercialization is not assured.
Read more →MBOTMicrobot Medical Selected for Preliminary Inclusion to Russell Microcap Index
Microbot Medical Inc. has been selected for preliminary inclusion in the Russell Microcap Index, which is expected to take effect on June 30, 2025. This milestone positions Microbot Medical among the largest U.S. stocks, potentially attracting institutional investors. The company's innovative LIBERTY Endovascular Robotic System aims to enhance patient care, although it faces challenges including the need for regulatory approvals and financial sustainability.
Read more →MBOTMicrobot Medical Bolsters Commercial Leadership Team with the Addition of Experienced Healthcare Officers The addition of a seasoned VP of Marketing compliments the recent hiring of the Company's VP of Sales to establish
Microbot Medical Inc. announced the addition of seasoned professionals to its U.S. commercial leadership team, enhancing its capabilities in marketing and human resources. The company's preparations for the U.S. launch of its LIBERTY Endovascular Robotic System are underway, pending FDA clearance expected in the second quarter of 2025. The hiring of a VP of Marketing and a Director of Human Resources reflects the company's commitment to effective commercialization strategies. Positive data from recent studies also bolster confidence in the product's anticipated market performance.
Read more →MBOT▲ +18.7%on this news· ran to +64% by day 3
Microbot Medical Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY Endovascular Robotic System Successful robotic navigation was achieved in every case and met the
Microbot Medical Inc. (NASDAQ: MBOT) has published results from its ACCESS-PVI pivotal trial, showcasing 100% success in robotic navigation with the LIBERTY Endovascular Robotic System. The trial demonstrated a significant 92% reduction in radiation exposure for patients, with no reported adverse events, heightening the system's feasibility in clinical settings. The company is preparing for potential FDA clearance and market launch, affirming confidence in the system's future reception. The trial was conducted across three prominent medical centers in the U.S.
Read more →MBOTREMINDER : Microbot Medical Announces Data from the Company's ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting Company Reaffirms Expected Timing of FDA Deci
Microbot Medical announced that it will present data from the ACCESS-PVI trial at the Society of Interventional Radiology Annual Meeting on April 2. This marks the first podium presentation of the trial's data, which evaluates the LIBERTY Endovascular Robotic System's performance and safety. The company also reiterated its expectation for the FDA's decision on the 510(k) clearance of LIBERTY within the current second quarter. This event signifies a critical step in the company's journey toward commercialization.
Read more →MBOTMicrobot Medical Appoints Seasoned Endovascular Sales Executive to Lead its U.S. Sales Activities for LIBERTY Endovascular Robotic System Mr. Paul Mullen Most Recently Served as the Director of Sales at Inari Medical whi
Microbot Medical has appointed Paul Mullen as its new Vice President of Sales, who will oversee the U.S. commercial sales for the LIBERTY Endovascular Robotic System. Mullen brings considerable experience from his previous role at Inari Medical, where he successfully launched multiple medical devices. With the anticipated FDA decision expected in the second quarter of 2025, the appointment symbolizes a key step in building the company’s commercial readiness. The company aims to redefine endovascular robotics and improve patient care by developing a fully disposable robotic system.
Read more →MBOTRobotic Telesurgery Data from Collaboration with Corewell Health Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting Research Collaboration demonstrates the feasibility of using the LIBER
Microbot Medical Inc. has announced that its collaboration with Corewell Health has achieved a significant milestone by developing the LIBERTY Endovascular Robotic System for telerobotic procedures. The research project, which assesses the system's feasibility across two sites, has been accepted for presentation at the Cardiovascular Research Technologies annual meeting in March 2025. This study indicates progress in incorporating telesurgery into healthcare, potentially enhancing access to quality care for patients in remote areas. The LIBERTY system's innovative design may change traditional approaches to endovascular procedures.
Read more →MBOT▼ -12.1%on this news
Microbot Medical Closes $13 Million Registered Direct Offering
Microbot Medical Inc. has successfully closed a registered direct offering, raising approximately $13 million in gross proceeds from the sale of over 6 million shares of common stock. In addition, the company issued short-term preferred investment options in a concurrent private placement. The raised funds will be utilized for the continued development and commercialization efforts of its LIBERTY Robotic System, along with general corporate purposes. The offering was facilitated by Wainwright & Co. as the exclusive placement agent.
Read more →MBOT▼ -9.4%on this news· ran to -20% by day 1shared move
Microbot Medical Announces $13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. announced a registered direct offering of 6,103,289 shares at a price of $2.13 per share, expected to raise approximately $13 million. The proceeds will support the development of the LIBERTY Robotic System and the expansion of its IP portfolio. A concurrent private placement will issue unregistered investment options, and the closing of these transactions is anticipated around February 11, 2025. However, the completion of the offerings is contingent upon stockholder approval, adding an element of uncertainty to the process.
Read more →MBOT▲ +13.8%on this news· ran to +41% by day 3
Microbot Medical Announces Late-Breaking Abstract Acceptance at the Society of Interventional Radiology Annual Meeting Acceptance reflects the high interest of the SIR scientific committee on the emerging role of endovas
Microbot Medical Inc. announced the acceptance of a late-breaking abstract for its LIBERTY Endovascular Robotic System at the Society of Interventional Radiology annual meeting. The abstract will detail findings from the ACCESS-PVI trial, focusing on the system's performance and safety in peripheral vascular interventions. CEO Harel Gadot emphasized the significance of presenting this data to potential users of LIBERTY. The presentation is scheduled for April 2, 2025, in Nashville, TN.
Read more →MBOT▲ +11%on this news· ran to +24% by day 3
Microbot Medical Strengthens Its Management Team in Support of the Anticipated Commercial Launch of LIBERTY Operations Leader to Enhance Operational Efficiencies by Managing Production Scale-up and Cost Reduction Activit
Microbot Medical has appointed Michal Ahuvia as Director of Operations to support the anticipated commercial launch of its LIBERTY Endovascular Robotic System, expected in Q2 2025. Ahuvia brings over 20 years of operational experience and is tasked with improving production efficiencies and managing production scale-up processes. This strategic hiring is seen as crucial for achieving the company’s commercialization goals. However, the firm faces various risks, including regulatory approvals and market conditions, that could impact its future success.
Read more →MBOT▼ -7.8%on this news· ran to -20% by day 1
Microbot Medical Strengthens Its Commercial Capabilities with the Addition of David J. Wilson to the Board of Directors
Microbot Medical Inc. has announced the election of David J. Wilson to its Board of Directors as part of its strategy to enhance its commercial capabilities. Wilson, a seasoned healthcare executive with extensive experience in endovascular devices, is expected to provide crucial guidance as the company prepares for the impending commercial launch of its LIBERTY® Endovascular Robotic System in the second quarter of 2025. He replaces Yossi Bornstein, who has served since the company's public debut in 2016. The transition reflects Microbot's commitment to strengthening its leadership team amid imminent market entry.
Read more →MBOTMicrobot Medical Closes $8.6 Million Registered Direct Offering
Microbot Medical Inc. has successfully closed an $8.6 million registered direct offering, enabling the sale of 3,788,550 shares at $2.27 each. The company plans to utilize the proceeds for the development and commercialization of its LIBERTY® Robotic System, as well as for general corporate purposes. Additionally, the offering included unregistered short-term series H preferred investment options. The company faces uncertainties regarding regulatory approvals and market conditions.
Read more →MBOT▼ -33.9%on this news· ran to -46% by day 3shared move
Microbot Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. has announced a registered direct offering of 3,788,550 shares of common stock priced at $2.27 per share, aiming to raise approximately $8.6 million in gross proceeds. This financing, which includes concurrent private placement options, is intended to further the development and commercialization of the LIBERTY Robotic System. The closing of this offering is anticipated on January 9, 2025, contingent upon satisfying standard closing conditions. The funds are designated for ongoing regulatory activities and expansion of the company’s existing intellectual property portfolio.
Read more →MBOTMicrobot Medical Raises a Total of Approximately $11.8 Million in Gross Proceeds from Registered Direct Offering and Previously Announced ATM Facility
Microbot Medical Inc. has successfully closed a registered direct offering, raising approximately $11.8 million through the sale of shares and a concurrent private placement of investment options. The proceeds are earmarked for the development and commercialization of the LIBERTY® Robotic System and other corporate purposes. The company's growth strategy is subject to the necessary regulatory approvals and market conditions, which may influence their operating capacity going forward.
Read more →MBOT▲ +32.7%on this newsshared move
Microbot Medical Announces $7 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. announced a registered direct offering priced at-the-market under Nasdaq rules, aiming to raise $7 million by selling over 4 million shares at $1.75 each. The company plans to use the proceeds for the continued development and commercialization of its LIBERTY Robotic System, as well as for general corporate purposes. The closing of this offering is expected on or about January 7, 2025, dependent on customary closing conditions. Additionally, the company will issue preferred investment options in a concurrent private placement.
Read more →MBOT▲ +6.3%on this news· ran to +93% by day 3
Microbot Medical Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025
Microbot Medical Inc. has concluded 2024 by achieving crucial milestones, including the FDA 510(k) submission for its LIBERTY Endovascular Robotic System. The company has laid the groundwork for a commercial launch anticipated in Q2 2025, with significant achievements in clinical trials and quality certification. The Chief Executive Officer expressed optimism about future growth and has outlined key pre-commercial objectives. However, the company also faces challenges related to regulatory approvals and market conditions.
Read more →MBOTMicrobot Medical Announces FDA Submission for the Commercialization of the LIBERTY Endovascular Robotic System FDA 510(k) Submission Follows the Successful Completion of the Pivotal Human Clinical Trial FDA 510(k) Cleara
Microbot Medical Inc. has announced the submission of a 510(k) notification to the FDA for its LIBERTY Endovascular Robotic System, which is designed as the first single-use, fully disposable robotic system for peripheral vascular interventions. This 510(k) submission follows the successful completion of a pivotal human clinical trial. The company expects FDA marketing clearance in the second quarter of 2025, subsequently commencing U.S. commercialization. LIBERTY aims to improve procedure efficiency while addressing barriers to access advanced robotic systems.
Read more →MBOTMicrobot Medical CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access
Microbot Medical Inc. announced that CEO Harel Gadot will be featured in an interview on Benzinga All Access to discuss the company's LIBERTY Endovascular Robotic System. This system, the first single-use, fully disposable endovascular robotic system, aims to improve surgical efficiencies and reduce costs. The company has also submitted an FDA 510(k) application to commercialize LIBERTY, which could revolutionize access to robotic surgery. However, the company faces regulatory uncertainties and market risks as it transitions to a commercially focused entity.
Read more →MBOTMicrobot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY during 2Q 2025 U.S. Food and Drug Administration (FD
Microbot Medical Inc. has successfully completed its pivotal human clinical trial for the LIBERTY Endovascular Robotic Surgical System, with plans to file a 510(k) submission to the U.S. FDA by the end of 2024. Following the trial, the company is moving to accelerate its go-to-market strategy, anticipating commercial launch during the second quarter of 2025. The clinical trial aimed to assess LIBERTY's safety and performance in peripheral vascular interventions and received encouraging feedback from participating physicians. The results are set to be presented at a medical conference in early 2025.
Read more →MBOTMicrobot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up Confirms the Company on Track for FD
Microbot Medical Inc. has reported accelerated patient enrollment for its pivotal ACCESS-PVI human clinical trial of the LIBERTY Endovascular Robotic Surgical System. With 80% of patients having completed follow-up, the company anticipates completing the trial earlier than expected. Additionally, Microbot has successfully completed all necessary biocompatibility tests and has received final IDE approval from the FDA, positioning itself for a 510(k) submission by the end of 2024. The leadership expressed optimism regarding trial progression and collaboration among clinical sites.
Read more →MBOTMicrobot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System Completion of enrollment expected in Q4 with FDA submis
Microbot Medical Inc. has announced the successful enrollment of 50% of patients in its pivotal ACCESS-PVI human clinical trial for the LIBERTY Endovascular Robotic Surgical System. The company anticipates completing enrollment by Q4 2024, with a 510(k) submission to the FDA expected by the end of the year. Early feedback from physicians suggests the system is user-friendly and efficient. However, the company faces risks related to market conditions and regulatory approval processes that could impact commercialization timelines.
Read more →MBOT▼ -6.2%on this news
Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY Endovascular Robotic System The agreement follows the successful completion of Phase 1 which eva
Microbot Medical Inc. has entered a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery utilizing the LIBERTY Endovascular Robotic System. This agreement follows the successful completion of Phase 1, which confirmed the platform's technical viability. The Phase 2 project focuses on developing new telesurgery capabilities with simulated procedures between two Corewell Health facilities. The initiative is anticipated to enhance access to care in remote areas, led by Dr. Ryan Madder from Corewell Health's Interventional Cardiology team.
Read more →MBOTMicrobot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization The ISO 13485 certification is a validation of the Company's robust quality system
Microbot Medical Inc. (Nasdaq: MBOT) has announced the receipt of ISO 13485:2016 certification for its quality management system. This certification confirms the company's adherence to strict ISO standards necessary for regulatory compliance in the medical industry. It is seen as a significant step toward enabling future regulatory submissions and commercialization of their LIBERTY Endovascular Robotic Surgical System. The certification also aligns with European regulatory requirements and recent FDA updates, suggesting a proactive approach to market entry.
Read more →MBOTMicrobot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY Endovascular Robotic Surgical System The evaluation phase will explore the potential of integrating robotics, procedure
Microbot Medical Inc. has announced a collaboration with Emory University to explore the future capabilities of its LIBERTY Endovascular Robotic Surgical System. This agreement allows for the assessment of integrating robotics, imaging, and navigation into a single autonomous system for endovascular procedures. The project aims to improve healthcare access and standardize surgical outcomes, with Dr. Amir Pourmorteza leading the evaluation under Project Trita. Despite the innovative prospects, the partnership faces inherent risks related to regulatory approvals and potential market uncertainties.
Read more →MBOTMicrobot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center As the third and final clinical site, Memorial Sloan Kettering C
Microbot Medical Inc. has completed the enrollment of clinical sites for its pivotal human clinical trial with the addition of Memorial Sloan Kettering Cancer Center. This site joins Brigham and Women's Hospital and Baptist Hospital of Miami in conducting the trial. The investigational LIBERTY Endovascular Robotic Surgical System aims to enhance endovascular procedures by minimizing equipment size and operational strain. The trial is expected to support future marketing submissions to the FDA, as endorsed by the principal investigator, Dr. Francois Cornelis.
Read more →MBOTMicrobot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial Baptist Hospital of Miami is the second site to perform clinical procedures as part of the Company's Pivotal Human Clinical Tri
Microbot Medical has announced the commencement of patient enrollment in its pivotal human clinical trial for the LIBERTY Endovascular Robotic Surgical System at Baptist Hospital of Miami. This prestigious institution becomes the second site to conduct clinical procedures, following Brigham & Women's Hospital. The trial's aim is to support future FDA submissions for commercialization, marking a significant step in robotic surgical technologies. CEO Harel Gadot expressed optimism about the rapid progress being made with trials at two locations, although concerns regarding regulatory pathways and operational disruptions remain.
Read more →MBOTMicrobot Medical Enrolled the First Patient in its Pivotal Human Clinical Trial The first clinical case was performed at Brigham and Women's Hospital The clinical trial is expected to support the future submission to the
Microbot Medical Inc. announced the successful enrollment of the first patient in its pivotal human clinical trial for the LIBERTY Endovascular Robotic Surgical System at Brigham and Women's Hospital. This milestone is expected to facilitate future submission to the FDA for commercialization. The clinical trial, led by Dr. Dmitry Rabkin, is aimed at improving the use of surgical robotics in endovascular procedures. The company is optimistic about the timeline and potential impact of the LIBERTY system on patient care and surgical practices.
Read more →MBOT▲ +6.1%on this newsshared move
Microbot Medical Partners with Baptist Hospital of Miami to Participate in its Pivotal Human Clinical Trial Following the Company's recent FDA approval to commence its pivotal human clinical trial, Baptist Hospital of Mi
Microbot Medical Inc. has received FDA approval to commence its pivotal human clinical trial for the LIBERTY Endovascular Robotic Surgical System. Baptist Hospital of Miami, alongside Brigham and Women's Hospital, will participate in the trial, with Dr. Ripal Gandhi as the principal investigator. The company aims to improve endovascular procedures by reducing the need for expensive equipment and minimizing radiation exposure. The leadership at Microbot Medical expresses optimism regarding the rapid enrollment of trial sites, indicating strong interest in the innovative technology.
Read more →MBOTMicrobot Medical Partners with Brigham and Women's Hospital for Its Pivotal Human Clinical Trial
Microbot Medical has partnered with Brigham and Women's Hospital to initiate its pivotal human clinical trial for the LIBERTY® Endovascular Robotic Surgical System, having received FDA approval to commence the trial. The site has been prepared with training for clinical staff and delivery of investigational systems. Dr. Dmitry Rabkin will lead the study at this site, enhancing collaboration with a prestigious medical institution. While the development signifies progress in surgical robotics, there remain risks regarding trial outcomes and market conditions.
Read more →MBOTMicrobot Medical Announces Brigham and Women's Hospital as a Site for its Pivotal Human Clinical Trial The Site Initiation Visit for the BWH clinical staff is complete and a shipment of LIBERTY investigational units was
Microbot Medical Inc. announced that Brigham and Women's Hospital will serve as a key site for its pivotal human clinical trial of the LIBERTY Endovascular Robotic Surgical System. The Site Initiation Visit has been completed, with BWH clinical staff trained on the protocols and investigational units delivered. Dr. Dmitry Rabkin will act as the principal investigator at BWH, and the company aims to involve additional leading centers in the trial. This system is positioned to enhance endovascular procedures significantly.
Read more →MBOT▼ -17.4%on this news
Microbot Medical Announces Closing of $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. has successfully closed a registered direct offering, raising approximately $2.35 million by selling 1,566,669 shares of common stock at a price of $1.50 per share. The proceeds from the offering will be directed towards the development and commercialization of the company's LIBERTY Robotic System, as well as for working capital and other corporate purposes. In conjunction, the company issued unregistered series F preferred investment options that can be exercised to purchase additional shares. The response to this offering suggests growing interest in Microbot's technological advancements, although it comes with inherent regulatory risks.
Read more →MBOT▲ +38%on this newsshared move
Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial The trial will be conducted in the US and its results will complement the preclinical data on the LIBERTY Endovascular Robotic S
Microbot Medical Inc. has received FDA approval to move forward with its pivotal human clinical trial for the LIBERTY Endovascular Robotic Surgical System. The trial will take place in the U.S., and the company is partnering with leading academic medical centers for the study. This initiative follows extensive preclinical studies and is expected to pave the way for potential regulatory clearance and commercialization of the system. The innovative LIBERTY system aims to transform endovascular procedures by reducing the need for conventional large equipment and enhancing accessibility for patients.
Read more →MBOT▲ +38%on this newsshared move
Microbot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. has announced a registered direct offering priced at $1.50 per share, aiming to raise approximately $2.35 million. The proceeds from this offering are intended for the advancement of the LIBERTY Robotic System and the development of additional applications. The closing of the offering is anticipated around June 4, 2024, contingent upon the satisfaction of customary conditions. The company is addressing forward-looking statements regarding the success of their technological developments and potential impacts from external factors.
Read more →MBOT▲ +7.8%on this news
Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health The next step of the collaboration will explore potential future applications of the LIBERTY system, including it
Microbot Medical Inc. has completed the first phase of its collaboration with Corewell Health, which showcased the technical capabilities of its LIBERTY Endovascular Robotic Surgical System. This partnership aims to explore remote robotic surgical applications, enhancing endovascular procedures. The outcomes have been positively received, with findings published in the Journal of the American College of Cardiology. The next steps in the collaboration will further investigate potential uses of the technology in clinical settings.
Read more →MBOTMicrobot Medical Shares Status Following Recent Geopolitical Events All Regulatory, Clinical, Operational and Pre-Commercial Activities Continue to Stay on Track Despite the On-going Situation in Israel Company Believes
Microbot Medical announced that despite ongoing geopolitical tensions in Israel, its regulatory, clinical, operational, and pre-commercial activities are on track. The company is working towards achieving its regulatory milestones with the FDA and has completed an internal audit in preparation for ISO certification. Additionally, it has established a sufficient inventory of its LIBERTY Endovascular Robotic Surgical System and is engaging in discussions with multiple strategic partners for commercialization. The CEO expressed confidence in the company's progress and anticipated milestones.
Read more →MBOTMicrobot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US
Microbot Medical Inc. has officially submitted an Investigational Device Exemption (IDE) application to the FDA to initiate its pivotal clinical trial for the LIBERTY Endovascular Robotic Surgical System in the U.S. This move follows successful preclinical activities that provided crucial safety and effectiveness data. The company aims to enhance surgical robotics in endovascular procedures and believes its technology could transform accessibility for patients. The approval of the IDE is a significant step for the company's journey towards achieving FDA clearance.
Read more →MBOT▼ -5.4%on this news
Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters All of the cash payable to the plaintiffs in the settlement will be covered by Microbot's insurance carrier
Microbot Medical Inc. has announced a Settlement Agreement and Release with several asset management firms, resolving all claims from a lawsuit related to a securities purchase agreement. The majority of the settlement payment will be covered by the company's insurance, ensuring no adverse impact on its cash position or balance sheet. CEO Harel Gadot emphasized that this resolution will allow the company to concentrate on future milestones, including the IDE submission to the FDA and the commencement of its first human clinical trial. Overall, this mark's a significant step toward stability and focus for the company.
Read more →MBOT▲ +6.3%on this news
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study Following the recent positive results of its pivotal GLP pre-clinical study, the
Microbot Medical Inc. has announced its expansion of clinical infrastructure in the U.S. to support an upcoming IDE submission for its first human clinical study. This move follows positive outcomes from its pivotal GLP pre-clinical study. The company has appointed a Clinical Research Associate to reinforce the clinical team led by Dr. Juan Diaz-Cartelle, enhancing the execution capabilities for their LIBERTY Endovascular Robotic Surgical System. The system is designed to simplify vascular procedures while improving accessibility and reducing operational burdens.
Read more →MBOT▼ -20%on this news· ran to -35% by day 1
Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Microbot Medical Inc. has announced an agreement for the immediate exercise of preferred investment options, which is expected to bring in approximately $2.73 million in gross proceeds. The shares are offered at a reduced exercise price of $1.62 and will be used to further develop the LIBERTY Endovascular Robotic Surgical System. The offering is set to close around January 3, 2024, contingent upon satisfying customary closing conditions. Additionally, Microbot plans to file a registration statement with the SEC for the resale of shares from the offering.
Read more →MBOT▲ +55.3%on this newsshared move
Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met
Microbot Medical Inc. has announced the successful completion of its GLP pivotal pre-clinical study involving the LIBERTY® Endovascular Robotic Surgical System. The study, conducted by leading interventional radiologists, met all defined study objectives and has led to positive histopathology outcomes. The company is now poised to move forward to human clinical studies, with plans to submit an IDE application to the FDA soon. This significant milestone reflects a transition for Microbot Medical into the clinical and regulatory phase of development.
Read more →MBOTMicrobot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY Endovascular Robotic Surgical System for Telerobotic The first phase in the collaboration will evaluate the current state of the LIBERTY R
Microbot Medical Inc. has announced a collaboration with Corewell Health to advance the LIBERTY Endovascular Robotic Surgical System, focusing on telerobotic procedures. This partnership aims to enable remote access to surgical robots, potentially improving healthcare delivery, especially in rural areas. Led by Dr. Ryan Madder, the initiative is seen as a significant step in enhancing procedural efficiency and accessibility. However, Microbot acknowledges various risks associated with market conditions and the need for future funding.
Read more →MBOTMicrobot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study The final histopathology and lab report supplements
Microbot Medical Inc. announced the successful completion of its GLP pivotal pre-clinical study, which is essential for its IDE submission to begin human clinical studies. Conducted using a porcine model, the study involved 96 robotic navigations utilizing the LIBERTY Endovascular Robotic Surgical System. The results demonstrated positive histopathological outcomes, bolstering the company’s confidence to advance to the next phase of development. This milestone signifies a critical transition for Microbot Medical as it moves from research and development into regulatory and clinical stages.
Read more →MBOTMicrobot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz-Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities The former Senior Medical Director for the P
Microbot Medical Inc. has appointed Dr. Juan Diaz-Cartelle as its new Chief Medical Officer, effective December 1, 2023. Dr. Diaz-Cartelle, previously with Boston Scientific Corporation, will lead the company's transition to increased clinical and regulatory activities in the U.S. This appointment comes as Microbot prepares for the clinical trials of its LIBERTY Endovascular Robotic Surgical System and aims to establish a stronger presence in the U.S. market. The company's leadership views this hiring as crucial to achieving FDA clearance and advancing robotic surgery standards.
Read more →MBOTMicrobot Medical Successfully Completed Integral Part of the Verification and Validation Process The V&V process is an additional key milestone toward regulatory submission and is required to continue the regulatory proc
Microbot Medical Inc. has successfully completed the Electromagnetic Compatibility (EMC) testing segment of its Verification and Validation (V&V) process for the LIBERTY Robotic Surgical System. This achievement marks a significant milestone towards the company's upcoming Investigational Device Exemption (IDE) submission to the FDA, which is necessary for initiating clinical trials. The completion of the EMC testing affirms the company's commitment to maintaining high safety and quality standards for their innovative technology, which aims to revolutionize endovascular surgical procedures.
Read more →MBOT▲ +8.7%on this newsshared move
Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark Office
Microbot Medical Inc. (NASDAQ: MBOT) has been granted a registered trademark by the U.S. Patent and Trademark Office for its LIBERTY Robotic Surgical System feature named "One & Done." This system is designed to enhance endovascular procedures by integrating various instruments and improving surgical outcomes. The trademark allows the company to strengthen its intellectual property portfolio while facing various challenges, including potential market risks, geopolitical issues, and uncertainties related to regulatory approvals. Despite these challenges, Microbot aims to revolutionize surgical robotics with its innovative technology.
Read more →MBOT▲ +6.2%on this news· ran to +26% by day 3
Microbot Medical Reveals Successful Short Term Follow Up Outcomes from its Pivotal Pre-Clinical Study Follow up visual examination three days after the procedures using the LIBERTY Robotic Surgical System, confirms 100%
Microbot Medical reported successful outcomes from its pivotal pre-clinical study of the LIBERTY Robotic Surgical System. The study demonstrated a 100% success rate in reaching animal study targets without any observed adverse events or complications. The company will submit an Investigational Device Exemption (IDE) application to the FDA once the validation process is completed. These results suggest promising safety and effectiveness for future human trials.
Read more →MBOTMicrobot Medical Received Confirmation for the Commencement of Its CE Mark Approval Process During the First Half of 2024 The Company's designated Notified Body confirmed dates for conducting audits for ISO 13485 certifi
Microbot Medical Inc. has received confirmation to start its CE Mark approval process for the LIBERTY Robotic Surgical System, scheduled for the first half of 2024. The designated Notified Body has confirmed dates for ISO 13485 certification audits, which are essential for compliance with EU regulations. The company intends to carry out this process concurrently with its FDA regulatory efforts to facilitate global market entry. This announcement highlights the potential for the LIBERTY system to enhance surgical procedures by reducing equipment size and improving accessibility.
Read more →MBOT▼ -7.5%on this newsshared move
Microbot Medical Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company Braintree, Mass.
Microbot Medical Inc. announced that the United States District Court granted its motion for summary judgment and dismissed a counterclaim against it. The court fully adopted the Magistrate Judge's recommendation supporting Microbot's case. As a result, the company is now able to enforce a previous judgment in its favor, which was worth $484,614.30, marking a significant legal victory for the company.
Read more →MBOT▲ +15%on this newsshared move
Microbot Medical Announces Successful Initial Outcomes from Its Pivotal Pre-Clinical Study with the LIBERTY Robotic Surgical System - A total of 48 animal targets were reached with 100% usability and technical success an
Microbot Medical announced the successful initial outcomes of its pivotal pre-clinical study for the LIBERTY Robotic Surgical System. The study involved 48 animal targets and reported 100% usability and technical success with no adverse events observed. With the completion of verification and validation studies, the company plans to submit an Investigational Device Exemption (IDE) application to the FDA to advance to human clinical trials. The performance of the LIBERTY system positions it as a potential breakthrough in surgical robotics, aiming to improve clinical outcomes and accessibility.
Read more →MBOTMicrobot Medical Engages CRO to Support its Upcoming U.S. Pivotal Clinical Trial The engagement is an additional step in the Company's path towards marketing clearance with the
Microbot Medical Inc. has announced its partnership with a Contract Research Organization (CRO) to assist in its upcoming U.S. pivotal clinical trial for the LIBERTY Robotic Surgical System. This collaboration aims to enhance the company's clinical trial capabilities and navigate the FDA's regulatory landscape. The CRO, known for its expertise in vascular device trials, will provide crucial research management services and guidance throughout the trial process. The LIBERTY system is designed to improve endovascular procedures by reducing reliance on large equipment and minimizing radiation exposure.
Read more →MBOTMicrobot Medical Gains Global Recognition; Professor Vincent Vidal to Present an Abstract on The LIBERTY Robotic Surgical System at CIRSE 2023 The presentation follows successful extensive uses of the Company's endovascu
Microbot Medical Inc. announces that its LIBERTY Robotic Surgical System will be showcased in an abstract presentation at CIRSE 2023 by Professor Vincent Vidal. Following successful pre-clinical studies, the abstract highlights the positive experiences of interventional radiologists with the robotic system. This recognition is seen as crucial as the company moves toward initiating its First in Human clinical trials and seeks regulatory approval from the FDA and MDR in Europe.
Read more →MBOTMicrobot Medical Boosts Manufacturing and Commercialization Capabilities for its Robotic Surgical System The Agreement with a leading full turnkey manufacturer further strengthens the Company's progression towards expect
Microbot Medical Inc. has signed a manufacturing agreement with B.Y. Medimor Ltd. to enhance the commercialization of its LIBERTY Robotic Surgical System. This system, which aims to transform endovascular procedures, is set to enter its first human clinical trials. The agreement is expected to facilitate the initial marketing of LIBERTY following regulatory requirements. Additionally, the company's CTO emphasized the importance of this partnership in advancing their clinical and commercial objectives.
Read more →MBOTMicrobot Medical Strengthens Its Position Among US Interventional Radiologists by Appointing Professor Francois H. Cornelis to Its Scientific Advisory Board Professor Francois H. Cornelis is a world renown neuro interven
Microbot Medical has strengthened its scientific advisory board by appointing Professor Francois H. Cornelis, a renowned neuro interventional radiologist. Professor Cornelis specializes in minimally invasive therapies and has extensive experience in treating tumors and cancer-related pain. His inclusion is viewed as a significant endorsement for Microbot's innovative LIBERTY Robotic Surgical System, aiming to transform endovascular procedures. The company anticipates that his contributions will aid in upcoming clinical trials and collaborations with major medical institutions.
Read more →MBOTMicrobot Medical Engaging with a Leading Notified Body to Secure CE Mark for Sales in Europe Engagement includes audit plans for ISO 13485 certification, to pave the way for obtaining CE Mark for clearance of sales in th
Microbot Medical Inc. has begun the process of securing a CE Mark to sell its LIBERTY Robotic Surgical System in Europe by engaging with a leading Notified Body. This engagement includes audit plans for achieving ISO 13485 certification, necessary for compliance with European Medical Device Regulations (MDR). The LIBERTY system aims to transform endovascular procedures by providing a single-use solution that minimizes equipment costs and reduces radiation exposure for physicians. Positive results from pre-clinical studies further support the system's potential in the market.
Read more →MBOTMicrobot Medical Expands its Physician Support with the Addition of Leading Italian Interventional Radiologist Irene Bargellini, M.D., to its Scientific Advisory Board Believes that the reduction in radiation exposure th
Microbot Medical Inc. has appointed Dr. Irene Bargellini, a leading Italian interventional radiologist, to its Scientific Advisory Board. This move is expected to bolster the company's efforts towards the commercialization of its LIBERTY Robotic Surgical System, which aims to reduce radiation exposure during procedures. Dr. Bargellini's expertise in oncologic imaging and interventional oncology is seen as instrumental in navigating entry into the Italian market. Her involvement is also anticipated to promote the technology among women in the field, potentially broadening the user base of the robotic system.
Read more →MBOTMicrobot Medical Successfully Completes an Extensive Pre-Clinical Study Performed in the US The study was conducted over two days by a team of global key opinion leaders and with participation of executives from the medi
Microbot Medical Inc. announced the successful completion of a pre-clinical study for their LIBERTY Robotic Surgical System, achieving a 100% success rate in reaching predetermined vascular targets without complications. The study included feedback from leading medical industry executives and key opinion leaders, indicating strong interest in the system’s remote operation features. The company aims to address current challenges in endovascular procedures, potentially improving clinical outcomes and accessibility. CEO Harel Gadot highlighted the importance of this study in supporting future commercialization efforts.
Read more →MBOTMicrobot Medical Raises a Total of $7.6 Million in Gross Proceeds from Four Recent Registered Direct Offerings
Microbot Medical Inc. has successfully closed its fourth registered direct offering, raising approximately $2 million and contributing to total gross proceeds of $7.6 million from four recent offerings. The funds will be utilized for development and commercialization of the LIBERTY Robotic System, among other general corporate purposes. The offerings included common stock sales and series D preferred investment options. However, the securities sold are unregistered, raising potential regulatory risks around their future sale.
Read more →MBOT▼ -16.8%on this newsshared move
Microbot Medical Announces $2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Microbot Medical has announced a $2 million registered direct offering of shares at a price of $3.25 per share. The offering, which includes series D preferred investment options, is designed to fund the continued development and commercialization of the LIBERTY Robotic System and other corporate needs. The completion of this offering is expected to occur shortly, pending the satisfaction of customary closing conditions. The funding aims to enhance clinical outcomes through innovative robotic technologies.
Read more →MBOTMicrobot Medical Expand IP protection in Japan Received Grant of Protection for a Design Patent in Japan Covering its Innovative LIBERTY Robotic Drive
Microbot Medical Inc. announced the grant of a design patent from the Japan Patent Office for its LIBERTY Robotic Drive, enhancing its intellectual property portfolio. This patent adds to the company's existing protections in major regions, including the U.S., Europe, and Israel. The LIBERTY Robotic Surgical System aims to improve endovascular procedures by reducing equipment size and enhancing accessibility. The company sees this development as a validation of its commitment to advancing robotic technologies in healthcare.
Read more →MBOTMicrobot Medical Expand IP protection in Japan
Microbot Medical Inc. has announced the expansion of its intellectual property portfolio with the receipt of a Design Patent from the Japan Patent Office for the innovative design of the robotic drive of its LIBERTY Robotic Surgical System. This patent complements prior protections for the LIBERTY system and its remote controller design, with similar patents granted in the U.S., Europe, and Israel. The company views this milestone as a validation of its commitment to advancing robotic surgical technologies and improving accessibility for healthcare professionals and patients.
Read more →MBOT▲ +7.3%on this newsshared move
Microbot Medical Announces Multiple Peer Reviewed Abstracts Accepted by The Cardiovascular and Interventional Radiological Society of Europe Company Believes the Continuous Accumulation of Peer-Reviewed Data will Acceler
Microbot Medical Inc. announced the acceptance of two peer-reviewed abstracts at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe, showcasing their LIBERTY Robotic Surgical System. The acceptance reflects the enthusiasm of Key Opinion Leaders engaged in pre-clinical studies and demonstrates confidence in the system’s potential. This peer-reviewed data is seen as crucial for the company as it proceeds towards human clinical trials and regulatory approval, aiming for broader adoption of its technology. The system aims to streamline surgical robotics in endovascular procedures while enhancing patient outcomes.
Read more →MBOT▲ +10.4%on this news· ran to +31% by day 1
Microbot Medical Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. announced the successful closing of a $1.5 million registered direct offering, consisting of 701,756 shares of its common stock priced at $2.1375 each. In conjunction with this, the company also issued unregistered series C preferred investment options. The gross proceeds will support the development and commercialization of the LIBERTY Robotic System, as well as other corporate needs. H.C. Wainwright & Co. acted as the exclusive placement agent for these offerings.
Read more →MBOT▼ -18.5%on this newsshared move
Microbot Medical Receives a Non-Dilutive Grant from The Israel Innovation Authority Supporting the Development of the Manufacturing Process for its Endovascular Surgical Robotic System
Microbot Medical Inc. has secured a non-dilutive grant of approximately $440,000 from the Israel Innovation Authority to enhance the manufacturing process for its LIBERTY Robotic Surgical System. This represents the company's first approval for funding aimed at transitioning from development to manufacturing, reflecting recent milestones achieved. The grant is expected to bolster Microbot's manufacturing capabilities while maintaining a competitive edge and is viewed positively by management. However, there are obligations for royalty payments on future sales linked to this grant.
Read more →MBOT▼ -18.5%on this newsshared move
Microbot Medical Announces $1.5 Million Registered Direct Offering Priced At-The- Market under Nasdaq Rules
Microbot Medical Inc. has announced a registered direct offering to sell 701,756 shares of its common stock at $2.1375 per share, raising approximately $1.5 million. Additionally, the company will issue series C preferred investment options to purchase up to 350,878 shares at an exercise price of $2.075 per share. The proceeds from these offerings are intended to support the development, commercialization, and regulatory activities related to the LIBERTY Robotic System. The completion of these offerings is contingent on certain customary closing conditions.
Read more →MBOTLIBERTY Robotic Surgical System Achieved Additional Milestone in its Path to First in Human and Regulatory Process The data collected from the usage and experience of the medical professionals in the formative study will
Microbot Medical Inc. has announced a significant milestone in the development of its LIBERTY Robotic Surgical System, which is designed for single-use in endovascular procedures. Medical professionals participated in a formative study that allowed them to use the system in a simulated environment, which confirmed the system's user-friendly design. Feedback from medical professionals was highly positive, highlighting the system's potential to improve surgical outcomes while increasing accessibility. The study's success is a crucial step towards Microbot's regulatory and market goals.
Read more →MBOT▲ +11%on this newsshared move
Lahey Hospital & Medical Center Agrees to become One of U.S. Sites for the LIBERTY Robotic System's First Human Trial This Significant Achievement Represents Major Progression Toward Regulatory and Commercialization Path
Microbot Medical Inc. announced a significant milestone as Lahey Hospital & Medical Center agreed to participate as one of the U.S. sites for the first human trial of the LIBERTY Robotic Surgical System. This marks a major step towards regulatory approval and commercialization of the system, which aims to enhance surgical procedures through robotic technology. The trial's success will hinge on Lahey's experience and the performance of the system during previous studies. The company plans to submit an Investigational Device Exemption application to the FDA as part of its regulatory pathway.
Read more →MBOT▼ -12.8%on this newsshared move
Microbot Medical Announces Closing of $2.66 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. (Nasdaq: MBOT) announced the closing of a $2.66 million registered direct offering, selling over 1.2 million shares at $2.20 each. Proceeds from the offering will be used to further develop its LIBERTY Robotic System, as well as for expansion and general corporate purposes. The company has also amended some existing warrants to reduce their exercise price, which may highlight certain financial challenges. The offering is pursuant to a previously filed shelf registration statement with the SEC.
Read more →MBOT▼ -31.3%on this newsshared move
Microbot Medical Announces $2.66 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. announced a registered direct offering to sell approximately 1.2 million shares of common stock at $2.20 per share, expected to raise $2.66 million. The funds will be directed toward the commercialization of its LIBERTY Robotic System and other business activities. Additionally, the company plans to amend existing warrants, reducing their exercise price to $2.20. The closing of the offering is subject to customary conditions and is anticipated to occur shortly.
Read more →MBOT▼ -31.3%on this newsshared move
Microbot Medical Announces Closing of $1.4 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
Microbot Medical announced the successful closing of a $1.4 million registered direct offering of its common stock, priced at $2.20 per share. The company plans to utilize the proceeds to advance the development and commercialization of its LIBERTY Robotic System, as well as for working capital and other corporate purposes. H.C. Wainwright & Co. served as the exclusive placement agent for the offering. Despite the positive aspects of the capital raise, the company faces risks including market conditions, regulatory challenges, and the need for future funding.
Read more →MBOT▲ +159.3%on this newsshared move
Microbot Medical Announces $1.4 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. announced a registered direct offering for 655,569 shares of common stock priced at $2.20 per share, aiming to raise approximately $1.4 million. The offering is part of a plan to fund the development and commercialization of its LIBERTY Robotic System. The closing of the sale is expected by May 24, 2023, pending customary closing conditions. Wainwright & Co. is acting as the exclusive placement agent for this offering.
Read more →MBOT▲ +159.3%on this newsshared move
Microbot Medical Achieved 100% Success Rate for LIBERTY in Extensive Pre-Clinical Animal Study Performed by Leading European Physicians A team of six leading European interventional radiologists used the LIBERTY Surgical
Microbot Medical has announced that its LIBERTY Surgical Robotic System has achieved a 100% success rate in a recent extensive pre-clinical animal study conducted by a team of six leading European interventional radiologists. The study involved a total of 48 catheterizations to various vascular targets, all reaching the intended locations successfully. The radiologists praised the system for its intuitive design and remote operation capabilities. Following this success, Microbot Medical aims to proceed to human clinical trials later this year.
Read more →MBOTMicrobot Medical to Enhance Focus on its Core Business and Prioritize Preparations for Regulatory and First in Human Clinical Cases Company will enable focus on its LIBERTY technology through the introduction of the Core
Microbot Medical has announced a new Core Business Focus Program aimed at enhancing its focus on the LIBERTY technology, which includes cost restructuring and the elimination of non-core technology expenses. The company plans to prioritize preparations for regulatory approvals and to conduct first-in-human clinical cases for its LIBERTY Robotic Surgical System in the latter half of 2023. By streamlining resources, Microbot aims to improve the efficiency of its operations and strengthen its core offerings in endovascular surgical robotics.
Read more →MBOTMicrobot Medical Initiates Preparations for First-In-Human (FIH) Cases in Brazil for the LIBERTY Robotic System Distinguished publisher and lecturer, Interventional Radiologist Prof. Francisco Cesar Carnevale Expected to
Microbot Medical Inc. has begun preparations for its First-In-Human clinical trial of the LIBERTY Robotic system in Brazil. This initiative involves collaboration with Prof. Francisco Cesar Carnevale from the University of Sao Paulo Medical School Hospital, a respected figure in the field. The company has previously executed over 100 pre-clinical catheterization procedures, showing the LIBERTY system's potential. The trials are contingent on completion of the verification process and obtaining necessary regulatory approvals.
Read more →MBOTMicrobot Medical Announces Final Data From Its Recent Animal Study Data supports next regulatory steps for the LIBERTY Robotic System
Microbot Medical Inc. announced that the data from an animal study of its LIBERTY Robotic System is promising, indicating the system's potential to improve surgical procedures. The report showed positive feedback from physicians and no adverse events during tests. However, some histopathology results were equivocal, suggesting that physiological responses could complicate interpretations. The company plans to leverage this data to pursue a U.S. Investigational Device Exemption.
Read more →MBOT▼ -17.4%on this newsshared move
Microbot Medical's LIBERTY Robotic System Surpasses 100 th Catheterization 95% success rate of reaching pre-determined vascular target with no intraoperative complications presented during pre-clinical studies
Microbot Medical Inc. (NASDAQ: MBOT) announced that its LIBERTY Robotic System has surpassed 100 catheterizations with a remarkable 95% success rate for reaching pre-determined vascular targets, all executed without intraoperative complications. This achievement underscores the system's consistent performance and safety. The company aims to leverage this positive data and operator feedback to further advance its regulatory process with the FDA, including submitting an Investigational Device Exemption (IDE) in the coming months. The system is designed to transform endovascular surgical robotics by simplifying procedures and enhancing accessibility.
Read more →MBOT▲ +5.9%on this news
Gerry O'Sullivan, the Latest Member to Join Microbot Medical's Scientific Advisory Board, to Leverage Extensive Interventional Radiology Experience to Progress the LIBERTY Robotic System Through Regulatory, Clinical and
Microbot Medical has announced that Professor Gerry O'Sullivan has joined its Scientific Advisory Board. With extensive experience in interventional radiology, O'Sullivan's involvement is expected to provide valuable insights as the company progresses its LIBERTY Robotic System through regulatory and clinical phases. The LIBERTY system is designed to address gaps in interventional technology, aiming to improve patient outcomes. Microbot Medical is optimistic about O'Sullivan's contributions in establishing Centers of Excellence ahead of human clinical trials.
Read more →MBOT▲ +15.7%on this news
Microbot Medical Launches Presence in the United Kingdom as Highly Accomplished Consultant Interventional Radiologist Professor Mark W. Little Joins its Scientific Advisory Board as Efforts to Commercialize the LIBERTY R
Microbot Medical Inc. has announced its entry into the UK market with the appointment of Professor Mark W. Little to its Scientific Advisory Board. Professor Little, a highly regarded Consultant Interventional Radiologist, is expected to contribute to the regulatory and commercialization efforts for the LIBERTY Robotic System. His extensive experience and recent positive evaluations of the LIBERTY system are anticipated to bolster Microbot's capabilities in advancing its innovative medical technologies.
Read more →MBOTMicrobot Medical Increases Presence in the EU with the Addition of Greece-based Key Opinion Leader Stavros Spiliopoulos, MD, PhD, EBIR-ES, FCIRSE, to its Scientific Advisory Board Internationally Recognized and Awarded I
Microbot Medical Inc. has announced the appointment of Dr. Stavros Spiliopoulos to its Scientific Advisory Board, enhancing its expertise in interventional radiology. Based in Greece, Dr. Spiliopoulos is recognized for his contributions to the field and will assist in the firm's regulatory and commercialization efforts for the LIBERTY Robotic System. This addition marks an important step in Microbot's strategy to expand its presence in the European market. The company's ongoing efforts to increase awareness of its robotic system are reportedly seeing success.
Read more →MBOT▼ -7%on this newsshared move
Microbot Medical's Chief Medical Officer Dr. Eyal Morag to Highlight Performance, Safety and Usability Benefits of the LIBERTY Robotic System During Podium Presentation at Prestigious Robotics Conference
Microbot Medical Inc.'s Chief Medical Officer, Dr. Eyal Morag, is set to present the performance, safety, and usability advantages of the LIBERTY Robotic System at the Israeli Conference on Robotics on March 28th. This system is notable as the first single-use endovascular robotic device designed to reduce physicians' radiation exposure and physical stress compared to traditional manual procedures. The presentation will include findings from feasibility studies conducted with experienced radiologists, showcasing key metrics such as performance and safety. The conference emphasizes the advancement of high-end robotics across various sectors, including healthcare.
Read more →MBOT▲ +7.1%on this news
Microbot Medical Leverages Recently Awarded Non-Dilutive Grant from the Israeli Government to Promote Marketing Activities Toward Commercialization of the LIBERTY Robotic System Engagement with Interventional Radiologist
Microbot Medical Inc. has received a NIS300,000 grant from Israel's Ministry of Economy to boost marketing efforts for its LIBERTY Robotic System. This funding is aimed at enhancing the company's profile among stakeholders in the U.S. market as it prepares for future commercialization. The grant is non-dilutive and can be repaid through future sales royalties. The company focuses on advancing its innovative micro-robotic technologies, with an emphasis on improving clinical outcomes and patient access.
Read more →MBOTMicrobot Medical Meeting with Key Opinion Leaders, Hospital Administrators, and Potential Strategic and Commercial Partners at the Society of Interventional Radiologist Annual Meeting Continues to Raise Awareness of the
Microbot Medical Inc. is participating in the Society of Interventional Radiologist (SIR) annual meeting to discuss their LIBERTY Robotic System, the first single-use endovascular robotic system. Company leaders are meeting with key opinion leaders and potential partners to share progress and gather feedback as they approach commercialization. The event, held from March 4th to 9th in Phoenix, aims to meet educational needs in interventional radiology. Microbot aims to ensure the LIBERTY system delivers superior patient care compared to current standards.
Read more →MBOT▲ +12.6%on this newsshared move
Microbot Medical Expands its Geographic Presence to South America with the Addition of Francisco C. Carnevale, MD, PhD, FSIR to its Scientific Advisory Board Increases Key Opinion Leaders to 13 Throughout the Americas, I
Microbot Medical Inc. has announced the addition of Dr. Francisco C. Carnevale to its Scientific Advisory Board, expanding its presence in South America. With this addition, the advisory board now consists of 13 key opinion leaders from various regions, including the U.S., Israel, and Europe. Dr. Carnevale's expertise in interventional radiology and his background in Prostatic Artery Embolization are anticipated to significantly contribute to the development and commercialization of the LIBERTY Robotic System.
Read more →MBOTMicrobot Medical's Remote Controller for the LIBERTY Robotic System Receives Design Patent Allowance in Japan Allows Endovascular Procedure to be Performed from the Cath-Lab Control Room, Potentially Minimizing Radiation
Microbot Medical Inc. announced that their LIBERTY Robotic System's remote controller has received a design patent allowance in Japan. This recognition adds to existing patents in the U.S. and Europe, and highlights the innovative nature of the device. It aims to reduce radiation exposure and physical strain on healthcare providers during endovascular procedures. The ergonomic design has received positive feedback from physicians, which is essential for improving patient care outcomes.
Read more →MBOTMicrobot Medical Welcomes Distinguished Interventional Cardiologist and Early Adopter of Endovascular Robotics to its Next “Access-Ability Live by MBOT” Webinar Series
Microbot Medical Inc. announced its upcoming webinar, 'Access-Ability Live by MBOT,' scheduled for February 8, 2023, featuring Dr. Giora Weisz, a noted interventional cardiologist. The webinar aims to engage stakeholders interested in the advancements of endovascular robotics. Hosted by Dr. Eyal Morag, the session will explore current and future landscapes in robotic-assisted medical technologies. It promises a platform for discussions among industry leaders on pivotal issues in endovascular procedures.
Read more →MBOTMicrobot Medical Announces MedTech Industry Veteran Joe Mullings will Moderate the Next Access-Ability Live by MBOT' Webinar Panel of Proven Medical Device Entrepreneurs and Surgical Robotics Pioneers Will Share Their Pe
Microbot Medical Inc. has announced that industry veteran Joe Mullings will moderate the upcoming Access-Ability Live webinar. Scheduled for January 10, 2023, the panel will include successful medical device entrepreneurs and pioneering figures in surgical robotics, focusing on innovations in the endovascular market. The series aims to highlight key insights and discussions around unmet medical needs and the impact of new technologies on surgical procedures. Microbot Medical, known for its LIBERTY Robotic System, emphasizes the importance of collaboration among healthcare professionals and industry experts during these webinars.
Read more →MBOTMicrobot Medical Announces the Participation of a Key Opinion Leader in the Endovascular Robotics Space at the Next "Access-Ability Live by MBOT" Webinar Series The Webinar, Which is Suitable to All Stakeholders Interest
Medical Announces the Participation of a Key Opinion Leader in the Endovascular Robotics Space at the Next "Access-Ability Live by MBOT" Webinar Series Webinar, Which is Suitable to All Stakeholders Interested in the Future of Endovascular Robotics, Will be Held on Wednesday, D
Read more →MBOTMicrobot Medical's Proprietary LIBERTY Robotic System Receives Third Patent Allowance in Israel Pace of Jurisdictional Allowances Parallels Pre-Clinical and Regulatory Progress
Medical's Proprietary LIBERTY Robotic System Receives Third Patent Allowance in Israel of Jurisdictional Allowances Parallels Pre-Clinical and Regulatory Progress Mass., December 8, 2022 - Microbot Medical Inc. (Nasdaq: MBOT) continues to strengthen its intellectual property (I
Read more →MBOTMicrobot Medical's Novel LIBERTY Robotic System Continues to be Validated with Latest U.S. Design Patent Allowance Advanced Features of Remote Controller Specifically Developed to Deliver an Enhanced User Experience Duri
Medical's Novel LIBERTY Robotic System Continues to be Validated with Latest U.S. Design Patent Allowance Features of Remote Controller Specifically Developed to Deliver an Enhanced User Experience During Endovascular Procedures Mass., November 18, 2022 - Microbot Medical Inc.
Read more →MBOT▲ +11.8%on this newsshared move
Microbot Medical Announces New Webinar Series to Engage Stakeholders with Experts in the Healthcare Space The Access-Ability Live" by MBOT will build an online community of healthcare industry leaders who are interested
Medical Announces New Webinar Series to Engage Stakeholders with Experts in the Healthcare Space Access-Ability Live" by MBOT will build an online community of healthcare industry leaders who are interested in robotics to come together and share their opinion and experience We
Read more →MBOTMicrobot Medical Receives Additional Patent Allowance in Israel for the LIBERTY Robotic System Corresponding Application Previously Granted in the U.S. as the Company Continues to Create Global Barriers to Entry for its
Medical Receives Additional Patent Allowance in Israel for the LIBERTY Robotic System Application Previously Granted in the U.S. as the Company Continues to Create Global Barriers to Entry for its Novel Technology Mass., November 3, 2022 - Microbot Medical Inc. (Nasdaq: MBOT) c
Read more →MBOTMicrobot Medical Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
HINGHAM, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering with a single institutional investor for the purchase and sale of 1,022,495 shares of the Company’s common
Read more →MBOT▼ -6%on this newsshared move
Microbot Medical Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Medical Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules Mass., Oct. 21, 2022 - Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and
Read more →MBOTMicrobot Medical Accomplishes the Next-Step in the Regulatory Process for the LIBERTY Robotic System
Medical Accomplishes the Next-Step in the Regulatory Process for the LIBERTY Robotic System Mass., October 18, 2022 - Microbot Medical Inc. (Nasdaq: MBOT), announced that it has submitted the anticipated follow-up pre-submission package for the LIBERTY Robotic System to ensure
Read more →MBOTMicrobot Medical Completes GLP Animal Study for the LIBERTY Robotic System
Medical Completes GLP Animal Study for the LIBERTY Robotic System Mass., October 13, 2022 - Microbot Medical Inc. (Nasdaq: MBOT) announced a significant development milestone as it completed the GLP animal study for the LIBERTY Robotic System, the first disposable robotic syste
Read more →MBOTMicrobot Medical Enhances Strategic Focus on its Endovascular Solutions
HINGHAM, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) has announced that, following the recent acquisition of the endovascular assets of Nitiloop Ltd. along with other significant developments regarding the LIBERTY® Robotic System, including the c
Read more →MBOTMicrobot Medical Receives Patent Allowance in Israel for the LIBERTY Robotic System Complements Existing Allowance in the U.S. as Global Jurisdictions Recognize the Uniqueness of the Technology
Medical Receives Patent Allowance in Israel for the LIBERTY Existing Allowance in the U.S. as Global Jurisdictions Recognize the Mass., October 10, 2022 - Microbot Medical Inc. (Nasdaq: MBOT) is continuing to expand its global intellectual property portfolio for the LIBERTY Ro
Read more →MBOT▼ -6.5%on this newsshared move
Microbot Medical Strengthens LIBERTY Robotic System Portfolio with Acquisition of Novel FDA-Cleared Devices Integration with the LIBERTY Robotic System & One & Done Technology May Enable Future Acceleration of Robotic Ad
Medical Strengthens LIBERTY Robotic System Portfolio with Acquisition of Novel FDA-Cleared Devices with the LIBERTY Robotic System & One & Done Technology May Enable Future Acceleration of Robotic Adoption; Represents an Additional Growth Opportunity by Accessing the $500 Milli
Read more →MBOT▲ +6.6%on this newsshared move
Microbot Medical Announce Strategic Addition to Scientific Advisory Board Appointment Award-Winning Interventional Radiologist in the NY Metro Area Adds Significant Depth and Experience
Medical Announce Strategic Addition to Scientific Advisory Board Appointment Interventional Radiologist in the NY Metro Area Adds Significant Depth and Experience Mass., October 4, 2022 - Microbot Medical Inc. (Nasdaq: MBOT), which continues to be committed to expanding its cap
Read more →MBOTMicrobot Medical Attracts Another Leading Physician and Expands Capabilities of its Scientific Advisory Board with Addition of Dr. Ripal Gandhi Miami-based Physician Specializes in Minimally Invasive Treatments for Perip
Medical Attracts Another Leading Physician and Expands Capabilities of its Scientific Advisory Board with Addition of Dr. Ripal Gandhi Physician Specializes in Minimally Invasive Treatments for Peripheral Vascular Disease, Cancer, and Other Diseases Mass., September 19, 2022
Read more →MBOTMicrobot Medical Enhances its Scientific Advisory Board (SAB) with its Newest Member Dr. Vincent Vidal Prominent France based interventional radiologist to leverage his expertise to assist the Company to achieve its futu
Medical Enhances its Scientific Advisory Board (SAB) with its Newest Member Dr. Vincent Vidal France based interventional radiologist to leverage his expertise to assist the Company to achieve its future objective for the LIBERTY Robotic System Mass., September 15, 2022 - Micr
Read more →MBOTMicrobot Medical to Review Recent Progress D uring H.C. Wainwright's 24th Annual Global Investment Conference Company Continues to Achieve Primary Objectives for its LIBERTY Robotic System in 2022
Medical to Review Recent Progress During H.C. Wainwright's 24th Annual Global Investment Conference Continues to Achieve Primary Objectives for its LIBERTY Robotic Mass., September 13, 2022 - Microbot Medical Inc. (Nasdaq: MBOT), announced that Harel Gadot, Chairman, President
Read more →MBOTMicrobot Medical to Review Recent Progress During H.C. Wainwright’s 24th Annual Global Investment Conference
HINGHAM, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that Harel Gadot, Chairman, President and CEO, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference being held in NYC. Mr. Gadot will provide an overvi
Read more →MBOT▲ +8.2%on this newsshared move
Microbot Medical Commenced its First Step in the Anticipated Regulatory Process for its LIBERTY Robotic System GLP Pre-Clinical Trial Commenced at a Leading Research Institute by Global Leaders in the Endovascular Space
Medical Commenced its First Step in the Anticipated Regulatory Process for its LIBERTY Robotic System Pre-Clinical Trial Commenced at a Leading Research Institute by Global Leaders in the Endovascular Space Mass., September 12, 2022 - Microbot Medical Inc. (Nasdaq: MBOT) announ
Read more →MBOTMicrobot Medical Strengthen its Scientific Advisory Board with the Recent Addition of Dr. Sebastian Flacke A global leader in the endovascular space will collaborate with the Company as it goes through the regulatory pro
Medical Strengthen its Scientific Advisory Board with the Recent Addition of Dr. Sebastian Flacke global leader in the endovascular space will collaborate with the Company as it goes through the regulatory process and future commercialization Mass., September 8, 2022 - Microbot
Read more →MBOTMicrobot Medical Secures Design Patent Grant in Europe for the LIBERTY Robotic System
Microbot Medical Secures Design Patent Grant in Europe for the LIBERTY Mass., September 6, 2022 - Demonstrating another key achievement, Microbot Medical Inc. (Nasdaq: MBOT), continues to execute its objective of expanding its global intellectual property (IP) portfolio for the
Read more →MBOTMicrobot Medical Confirms GLP Pre-Clinical Trial is on Track to Commence Later this Month
Medical Confirms GLP Pre-Clinical Trial is on Track to Commence Later this Month Mass., September 2, 2022 -Microbot Medical Inc. (Nasdaq: MBOT) announced, as part of the preparation for its anticipated U.S. Food and Drug Administration (FDA) and CE Mark submissions, that it rec
Read more →MBOTMicrobot Medical to Present the Self-Cleaning Shunt at the 16 th Asian Australasian Congress of Neurological Surgeons
Medical to Present the Self-Cleaning Shunt at the 16th Asian Congress of Neurological Surgeons Mass., August 18, 2022 - Microbot Medical Inc. (Nasdaq: MBOT), announced that it will be presenting the Company's Self-Cleaning Shunt (SCS) at the 16th Asian Australasian Congress of
Read more →MBOTMicrobot Medical to Review Recent Progress During Needham's Virtual Healthcare Conference
Medical to Review Recent Progress During Needham's Virtual Healthcare Conference Mass., April 11, 2022 - Microbot Medical Inc. (Nasdaq: MBOT), announced it will be presenting at the Annual Needham Virtual Healthcare Conference. Harel Gadot, Chairman, President and CEO will prov
Read more →MBOT▼ -5.4%on this newsshared move
Microbot Medical Continues to Strengthen Management Team as Rachel Vaknin Promoted to Chief Financial Officer Company Continues to Enhance Core Capabilities to Ensure Commercial and Financial Success
Medical Continues to Strengthen Management Team as Rachel Vaknin Promoted to Chief Financial Officer Continues to Enhance Core Capabilities to Ensure Commercial and Financial Success Mass., April 6, 2022 -Microbot Medical Inc. (Nasdaq: MBOT), seeking to continuously enhance its
Read more →MBOTMicrobot Medical Achieves Significant Regulatory Milestone for the LIBERTY Robotic System; Files FDA Pre-Submission Package for Regulatory Pathway Pre-Clinical Trial on Track for Third Quarter
Medical Achieves Significant Regulatory Milestone for the LIBERTY Robotic System; Files FDA Pre-Submission Package for Regulatory Trial on Track for Third Quarter Mass., March 31, 2022 - The operational momentum that Microbot Medical Inc. (Nasdaq: MBOT) experienced at the end o
Read more →MBOT▲ +65.1%on this news
Microbot Medical Announces Strategic Collaboration with Stryker Corporation to Develop the LIBERTY Robotic System for Neurovascular Applications
Medical Announces Strategic Collaboration with Stryker Corporation to Develop the LIBERTY Robotic System for Neurovascular Mass., December 27, 2021 - Microbot Medical Inc. (Nasdaq: MBOT) announced that it has entered into a strategic collaboration agreement with Stryker, a lead
Read more →MBOT▲ +7.1%on this news· ran to +77% by day 1shared move
Microbot Medical Secures Third Patent for the LIBERTY Robotic System in the United States; Success of Protecting Novel Intellectual Property Complements Recent Design Freeze Achievement
Medical Secures Third Patent for the LIBERTY Robotic System in the United States; Success of Protecting Novel Intellectual Property Complements Recent Design Freeze Achievement Mass., December 23, 2021 -Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Pate
Read more →MBOTMicrobot Medical Initiates Search for U.S. Clinical Sites for the LIBERTY Robotic System
Medical Initiates Search for U.S. Clinical Sites for the LIBERTY Robotic System Mass., December 22, 2021 - Microbot Medical Inc. (Nasdaq: MBOT) announced that it has and will continue to implement key initiatives that will prepare the LIBERTY Robotic System for commercializatio
Read more →MBOTMicrobot Medical Achieves Design Freeze of the LIBERTY Robotic System; Meets Previously Stated Milestone Timeline Live Demonstration of the LIBERTY Robotic System is Planned for January 10 th in San Francisco
Medical Achieves Design Freeze of the LIBERTY Robotic System; Meets Previously Stated Milestone Timeline Demonstration of the LIBERTY Robotic System is Planned for 10th in San Francisco, CA Mass., December 15, 2021 - Microbot Medical Inc. (Nasdaq: MBOT) achieved the design fr
Read more →MBOTMicrobot Medical Secures Additional Patent for the LIBERTY Robotic System in the United States
Medical Secures Additional Patent for the LIBERTY Robotic System in the United States Mass., November 19, 2021 -Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance for a second patent applicatio
Read more →MBOTMicrobot Medical Secures Patent for LIBERTY Robotic System in the United States
Medical Secures Patent for LIBERTY Robotic System in the United States Mass., October 6, 2021 - Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance covering the Company's LIBERTY Robotic System.
Read more →MBOTMicrobot Medical Secures Patent Allowance in China; Third Global Jurisdiction in 2021 to Recognize Novelty of One & Done' Technology
Medical Secures Patent Allowance in China; Third Global Jurisdiction in 2021 to Recognize Novelty of One & Done' Technology Mass., June 29, 2021, - Microbot Medical Inc. (Nasdaq: MBOT), announced that China has become the latest global jurisdiction to issue a Notice of Allowan
Read more →MBOTLeading Interventional Cardiologist Dr. Giora Weisz Joins Microbot Medical's Scientific Advisory Board
Interventional Cardiologist Dr. Giora Weisz Joins Microbot Medical's Scientific Advisory Board Mass., June 7, 2021 - Microbot Medical Inc. (Nasdaq: MBOT) continues its ongoing commitment to strengthen and broaden its capabilities as Giora Weisz, MD joined the Company's Scientif
Read more →MBOTMicrobot Medical Secures Additional Protection for the One and Done Guidewire Technology with another Notice of Patent Allowance
Microbot Medical Secures Additional Protection for the One and Done Guidewire Technology with another Notice of Patent Allowance HINGHAM, Mass., June 4, 2021, - Global patent jurisdictions continue to recognize Microbot Medical Inc.'s (Nasdaq: MBOT) innovative One & Done' gui
Read more →MBOTMicrobot Medical Granted Patent Allowance in Japan; Global Jurisdictions Recognizing Novel One & Done' Technology
Medical Granted Patent Allowance in Japan; Global Jurisdictions Recognizing Novel One & Done' Technology Mass., February 4, 2021 - Microbot Medical Inc. (Nasdaq: MBOT) has received official notification from the Japan Patent Office (JPO) that it intends to grant the Company a
Read more →MBOTMicrobot Medical Announces Successful Outcome of its Discussions with FDA Regarding Regulation of Self-Cleaning Shunt FDA Feedback Reflects Strength of Pre-Clinical Safety Data; Maintains Q3 2022 Projected Commencement o
Medical Announces Successful Outcome of its Discussions with FDA Regarding Regulation of Self-Cleaning Shunt Feedback Reflects Strength of Pre-Clinical Safety Data; Maintains Q3 2022 Projected Commencement of First-in-Human Clinical Trial Mass., January 27, 2021 - Microbot Medi
Read more →MBOTMicrobot Medical Enhances Scientific Advisory Board with World Renowned Interventional Radiologists Scientific Advisory Board Expanded with Additions of Global Medical Pioneers and Distinguished Thought Leaders
Medical Enhances Scientific Advisory Board with World Renowned Interventional Radiologists Advisory Board Expanded with Additions of Global Medical Pioneers and Distinguished Thought Leaders Mass., January 21, 2021 - Microbot Medical Inc. (Nasdaq: MBOT) continues to enhance its
Read more →MBOTMicrobot Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTY TM Robotic System Results Validate Findings of Initial Study; End Points Achieved with No Intraoperative Adverse Events Mana
Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTYTM Robotic Validate Findings of Initial Study; End Points Achieved with No Intraoperative Adverse Events Presenting at Needham Growth Conference Today at 2:00pm ET Mass., January 14, 2021 - T
Read more →MBOTMicrobot Medical Demonstrates Significant Progress in 2020; Outlines Anticipated Milestones for 2021 Hingham, MA
Medical Demonstrates Significant Progress in 2020; Outlines Anticipated Milestones for 2021 MA - January 11, 2021 - Microbot Medical Inc. (Nasdaq CM: MBOT) has concluded 2020 with the achievement of several operating and developmental milestones. The Company believes it is well
Read more →MBOTMicrobot Medical to Share Current Progress and Expected 2021 Milestones at Upcoming Conferences
Medical to Share Current Progress and Expected 2021 Milestones at Upcoming Conferences Mass., January 7, 2021 - Microbot Medical Inc. (Nasdaq: MBOT), announced that Harel Gadot, CEO, President and Chief Executive Officer, will be presenting virtually at two upcoming investor co
Read more →MBOTMicrobot Medical Secures Patents in Multiple Global Jurisdictions
Medical Secures Patents in Multiple Global Jurisdictions Mass., November 17, 2020 - Microbot Medical Inc. (Nasdaq: MBOT) announced that it has received patents in multiple jurisdictions, further demonstrating the Company's continued execution of expanding and protecting its Int
Read more →MBOTMicrobot Medical to Highlight Progress and Recent Achievements at H.C. Wainwright 6th Annual Israel Conference Webcast to be Held on Thursday November 12 th at 2:00pm
Medical to Highlight Progress and Recent Achievements at H.C. Wainwright 6th Annual Israel Conference to be Held on Thursday November 12th at 2:00pm ET Mass., November 9, 2020 - Microbot Medical Inc. (Nasdaq: MBOT) announced that Harel Gadot, the Company's CEO, President and C
Read more →MBOTMicrobot Medical Receives Notice of Allowance for U.S. Patent Covering a System for Reducing Dialysis Shunt Stenosis
Medical Receives Notice of Allowance for U.S. Patent Covering a System for Reducing Dialysis Shunt Stenosis Mass., October 7, 2020 - Microbot Medical Inc. (Nasdaq: MBOT) announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for p
Read more →MBOTMicrobot Medical Schedules Virtual Meeting to Address Increased Interest Following its Recent Announcement Webinar to be Held on Wednesday August 26 th at 11am
Medical Schedules Virtual Meeting to Address Increased Interest Following its Recent Announcement to be Held on Wednesday August 26th at 11am ET Mass., August 19, 2020 - Following its participation at the Needham Virtual Med Tech & Diagnostic conference, as well as the overwhe
Read more →MBOTMicrobot Medical Announces Successful Animal Study Utilizing Its LIBERTY TM Robotic System World's First Fully Disposable Surgical Robot Achieved all Endpoints with No Intraoperative Adverse Events Remotely Performed Pro
Medical Announces Successful Animal Study Utilizing Its LIBERTYTM Robotic System First Fully Disposable Surgical Robot Achieved all Endpoints with No Intraoperative Adverse Events Performed Procedures have the Potential to Reduce Radiation Exposure, Physical Strain and Cross Co
Read more →MBOTMicrobot Medical to Share Current Results of a Feasibility Animal Study Utilizing the LIBERTY Robotic System Results to be shared on August 17 th during Needham's Virtual Med Tech & Diagnostics Conference
Medical to Share Current Results of a Feasibility Animal Study Utilizing the LIBERTY Robotic System to be shared on August 17th during Needham's Virtual Med Tech & Diagnostics Conference Mass., August 13, 2020 - At the upcoming Needham Virtual Med Tech & Diagnostics Conference
Read more →MBOTMicrobot Medical Appoints the Co-Founder of Corindus Vascular Robotics to its Board of Directors Vascular Interventions Executive Will Contribute Significantly to the Development and Commercialization of LIBERTY Robotic
Medical Appoints the Co-Founder of Corindus Vascular Robotics to its Board of Directors Interventions Executive Will Contribute Significantly to the Development and Commercialization of LIBERTY Robotic System Mass., August 3, 2020 - Microbot Medical Inc. (Nasdaq: MBOT) has furt
Read more →MBOTMicrobot Medical Appoints Aileen Stockburger to the Board of Directors Proven Track Record of Numerous M&A and Strategic Collaboration Transactions
Medical Appoints Aileen Stockburger to the Board of Directors Track Record of Numerous M&A and Strategic Collaboration Transactions Mass., April 1, 2020 - Microbot Medical Inc. (Nasdaq: MBOT) announced the appointment of Aileen Stockburger to the Company's Board of Directors,
Read more →MBOTMicrobot Medical Appoints Eyal Morag M.D. as Chief Medical Officer
Medical Appoints Eyal Morag M.D. as Chief Medical Officer Mass., March 3, 2020 - Microbot Medical Inc. (NASDAQ: MBOT), announced the appointment of Eyal Morag, M.D., a leading radiologist, to Chief Medical Officer, effective immediately. In his new role, Dr. Morag will lead the
Read more →MBOTCORRECTING and REPLACING - Microbot Medical Appoints Eyal Morag M.D. as Chief Medical Officer
and REPLACING - Microbot Medical Appoints Eyal Morag M.D. as Chief Medical Officer Mass., March 03, 2020 (GLOBE NEWSWIRE) - In a release issued under the same headline earlier today by Microbot Medical Inc. (NASDAQ: MBOT), please note that in the first paragraph the appointment
Read more →MBOTMicrobot Medical Receives Intention to Grant from European Patent Office for a Patent Application Covering its Self-Cleaning Shunt
Medical Receives Intention to Grant from European Patent Office for a Patent Application Covering its Self-Cleaning Shunt Mass., Jan. 8, 2020 - Microbot Medical Inc. (Nasdaq: MBOT) has received an official communication from the European Patent Office (EPO) regarding its intent
Read more →MBOTMicrobot Medical Inc. Announces Closing of $10.0 Million Registered Direct Offering of Common Stock
HINGHAM, Mass., Dec. 31, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT) closed its previously announced registered direct offering of 900,901 shares of its common stock at a purchase price of $11.10 per share for total gross proceeds of approximately $10.0 million,
Read more →MBOTMicrobot Medical Inc. Announces $10.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
HINGHAM, Mass., Dec. 30, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that it has entered into definitive agreements with
Read more →MBOTMicrobot Medical Inc. Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Medical Inc. Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Mass., December 30, 2019 - Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical t
Read more →MBOTMicrobot Medical Inc. Announces Closing of $9.59 Million Registered Direct Offering of Common Stock
HINGHAM, Mass., Dec. 27, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT) closed its previously announced registered direct offering of 912,858 shares of its common stock at a purchase price of $10.50 per share for total gross proceeds of approximately $9.59 million,
Read more →MBOTMicrobot Medical Inc. Announces $9.59 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Medical Inc. Announces $9.59 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Mass., December 26, 2019 - Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical
Read more →MBOTMicrobot Medical to Unveil World's First Fully Disposable Robotic System for Endovascular Procedures Live Demonstration Planned for Monday
Medical to Unveil World's First Fully Disposable Robotic System for Endovascular Procedures Live Demonstration Planned for Monday, January 13, 2020, in San Francisco Breakthrough technology features compact design, remote operation capabilities and an integrated "One & Done " t
Read more →MBOTGlobal Jurisdictions Continue to Recognize Microbot Medical's Innovative Technology; Receives Notice of Allowance for a U.S. Patent Covering its TipCAT Technology Platform
Jurisdictions Continue to Recognize Microbot Medical's Innovative Technology; Receives Notice of Allowance for a U.S. Patent Covering its TipCAT Technology Platform Mass., Nov. 25, 2019 - Further demonstrating its commitment to expand and protect its Intellectual Property (IP)
Read more →MBOTMicrobot Receives Notice of Allowance for U.S. Patent Covering its TipCAT Technology Platform
Receives Notice of Allowance for U.S. Patent Covering its TipCAT Technology Platform Mass., Oct. 30, 2019 - In an expansion of its significant global patent estate, Microbot Medical Inc. (Nasdaq: MBOT) announced that the U.S. Patent and Trademark Office (USPTO) has issued a Not
Read more →MBOTMicrobot Medical Announces Outcome of Annual Meeting of Shareholders Maintains Regulatory Pre-Submission Timeline of the Self-Cleaning Shunt (SCS TM )
Medical Announces Outcome of Annual Meeting of Shareholders Regulatory Pre-Submission Timeline of the Self-Cleaning Shunt (SCS TM) Mass., September 13, 2019 - Having successfully executed a number of significant milestones over the past twelve months, Microbot Medical Inc. (NA
Read more →MBOTMicrobot Medical's Self-Cleaning Shunt (SCS ) Clearly Demonstrated the Ability to Prevent Shunt Occlusion in a Follow-up In-vitro Laboratory Study Positive Results Continue to Validate the Operational Effectiveness of th
Medical's Self-Cleaning Shunt (SCS ) Clearly Demonstrated the Ability to Prevent Shunt Occlusion in a Follow-up In-vitro Results Continue to Validate the Operational Effectiveness of the SCS Mass., September 10, 2019 - Having successfully concluded an independent in-vitro labor
Read more →MBOTMicrobot Medical to Demonstrate a Working Prototype of its Self-Cleaning Shunt at the Rodman & Renshaw Annual Global Investment Conference
Medical to Demonstrate a Working Prototype of its Self-Cleaning Shunt at the Rodman & Renshaw Annual Global Investment Conference Mass., September 5, 2019 - At the upcoming Rodman & Renshaw Global Investment Conference, Harel Gadot, CEO, President and Chairman of Microbot Medic
Read more →MBOTMicrobot Medical Receives Notice of Allowance from the Israel Patent Office for a Patent Application covering a System for Reducing Dialysis Shunt Stenosis
Medical Receives Notice of Allowance from the Israel Patent Office for a Patent Application covering a System for Reducing Dialysis Mass., July 24, 2019 - As it continues to expand and diversify its Intellectual Property (IP) portfolio, Microbot Medical (Nasdaq: MBOT) announced
Read more →MBOTMicrobot Medical Strengthens Global IP Portfolio with Canadian Notice of Allowance for a Patent Application for a Shunt Stenosis Prevention System HINGHAM, MA
Medical Strengthens Global IP Portfolio with Canadian Notice of Allowance for a Patent Application for a Shunt Stenosis Prevention MA - April 23, 2019 - As it continues to receive an overwhelming positive response from global jurisdictions, Microbot Medical Inc. (NASDAQ: MBOT)
Read more →MBOTMicrobot Medical Announces Notice of Intention to Grant of European Patent for Adjustable Guidewire Technology Hingham, MA
Medical Announces Notice of Intention to Grant of European Patent for Adjustable MA - March 4, 2019 - Further expanding its global IP portfolio, Microbot Medical Inc. (Nasdaq CM: MBOT) received an official communication from the European Patent Office regarding its intention to
Read more →MBOTMicrobot Medical Maintains 2019 Milestone Targets Following Recent Court Decision Hingham, MA
Medical Maintains 2019 Milestone Targets Following Recent Court Decision MA - March 1, 2019 - Microbot Medical Inc. (Nasdaq CM: MBOT) is maintaining its milestone targets for 2019 following the recently announced decision of the New York State Supreme Court to rescind the Stock
Read more →MBOTMicrobot Medical Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market
Medical Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Mass., January 23, 2019 - Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today
Read more →MBOTMicrobot Medical Showcases a Working Prototype of its Self-Cleaning Shunt Hingham, MA
Medical Showcases a Working Prototype of its Self-Cleaning Shunt MA - January 17, 2019 - Microbot Medical Inc. (Nasdaq CM: MBOT) demonstrated an activated Self-Cleaning Shunt (SCSTM) during recent one-on-one investor and analyst meetings in San Francisco, which took place durin
Read more →MBOTMicrobot Medical Inc. Announces $5.9 Million Registered Direct Offering Priced At-the-Market
Medical Inc. Announces $5.9 Million Registered Direct Offering Priced At-the-Market Mass., January 15, 2019 - Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today
Read more →MBOTMicrobot Medical Inc. Announces $3 Million Registered Direct Offering Priced At-the-Market
Medical Inc. Announces $3 Million Registered Direct Offering Priced At-the-Market Mass., Jan. 15, 2019 (GLOBE NEWSWIRE) - Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technolo
Read more →MBOTOverview Our Company Microbot is a pre-clinical medical device company specializing in the research, design and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery
is a pre-clinical medical device company specializing in the research, design and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Microbot is primarily focused on leveraging its micro-robotic technologies with t
Read more →MBOTMicrobot Medical Increases its Global IP Portfolio with Notice of Allowance from the European Patent Office
HINGHAM, Mass., Jan. 14, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ: MBOT), received a notification from the European Patent Office that it will grant a patent for Application No. 08738207, which covers the Company’s ViRob™ technology platform. Including this latest n
Read more →MBOTRecent Study Validates the Operational Effectiveness of Microbot Medical's Self-Cleaning Shunt (SCS TM )
Study Validates the Operational Effectiveness of Microbot Medical's Self-Cleaning Shunt (SCSTM) Mass., January 14, 2019 -Microbot Medical Inc. (NASDAQ: MBOT) announced today that it has validated the operational effectiveness of the Company's Self-Cleaning Shunt (SCSTM) in a re
Read more →MBOTMicrobot Medical Announces FDA Pre-Submission Milestones for 2019 Regulatory Pre-Submission of the Self-Cleaning Shunt (SCS TM ) Remains the Primary Operational Objective Hingham, MA
Medical Announces FDA Pre-Submission Milestones for 2019 Pre-Submission of the Self-Cleaning Shunt (SCS TM) Remains the Primary Operational Objective MA - January 7, 2019 - Microbot Medical Inc. (Nasdaq CM: MBOT) announced today anticipated operational and product milestones,
Read more →MBOTMicrobot Medical Announces Commencement of Pivotal Study for its Self-Cleaning Shunt Larger-Scale Pre-Clinical Trial to Validate Positive Outcome of Initial Study; Company Aims to Initiate Regulatory Submissions in mid-2
Medical Announces Commencement of Pivotal Study for its Self-Cleaning Shunt Pre-Clinical Trial to Validate Positive Outcome of Initial Study; Company Aims to Initiate Regulatory Submissions in mid-2019 MA - October 1, 2018 - Following the successful outcome of the initial study
Read more →MBOTMicrobot Medical Inc. to Present at the Ladenburg Thalmann Healthcare Conference Hingham, MA
Medical Inc. to Present at the Ladenburg Thalmann Healthcare Conference MA - October 1, 2018 - Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced th
Read more →MBOTMicrobot Medical Strengthens Global IP with Issued Patent in India Covering the Company's ViRob Technology Platform Hingham, MA
Medical Strengthens Global IP with Issued Patent in India Covering the Company's ViRob Technology Platform MA - June 25, 2018 - Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical
Read more →MBOTMicrobot Medical Inc. Announces European Patent Office's Intent to Grant Patent for Device for the Prevention of Shunt Stenosis Hingham, MA
Medical Inc. Announces European Patent Office's Intent to Grant Patent for Device for the Prevention of Shunt Stenosis Hingham, MA - June 18, 2018 - Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transformational
Read more →MBOTMicrobot Medical Inc. Schedules its Periodical Townhall Meeting for Monday, June 4th at 9:00 a.m., Eastern Time Hingham, MA
Medical Inc. Schedules its Periodical Townhall Meeting for Monday, June 4th at 9:00 a.m., Eastern Time MA - May 30, 2018 - Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technol
Read more →MBOTMicrobot Medical Announces Successful Completion of Pre-Clinical Study Performed at Washington University in St. Louis Significant Milestone Suggests Initial Safety Profile of the Self-Cleaning Shunt (SCS ) Product as th
Medical Announces Successful Completion of Pre-Clinical Study Performed at Washington University in St. Louis Milestone Suggests Initial Safety Profile of the Self-Cleaning Shunt (SCS ) Product as the Company Moves Forward to Next MA- May 29, 2018 - Microbot Medical Inc. (NASDA
Read more →MBOTMicrobot Medical Closes Acquisition of Novel Technology from CardioSert Ltd. Hingham, MA
Medical Closes Acquisition of Novel Technology from CardioSert Ltd. MA - May 25, 2018 - Microbot Medical Inc. (NASDAQ CM: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced the closi
Read more →MBOTMicrobot Medical Announces Receiving a Notification of Granting a Patent Right for its ViRob Technology Platform in China Hingham, MA
Medical Announces Receiving a Notification of Granting a Patent Right for its ViRob Technology Platform in China MA - May 23, 2018 - Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transformational micro-robotic me
Read more →MBOTMicrobot Medical Successfully Completes Pre-Clinical Study for its Self-Cleaning Shunt Data from Pre-Clinical Study Indicates the Self-Cleaning Shunt has the Potential to be a Viable Technology for Preventing Occlusion i
Medical Successfully Completes Pre-Clinical Study for its Self-Cleaning Shunt from Pre-Clinical Study Indicates the Self-Cleaning Shunt has the Potential to be a Viable Technology for Preventing Occlusion in Shunts Used to Treat Hydrocephalus MA- May 21, 2018 - Microbot Medica
Read more →MBOTMicrobot Medical Announces Receiving Notice of Allowance for a U.S. Patent covering its Self-Cleaning Shunt (SCS) Device Hingham, MA
Microbot Medical Announces Receiving Notice of Allowance for a U.S. Patent covering its Self-Cleaning Shunt (SCS) Device Hingham, MA - May 9, 2018 - Microbot Medical Inc. (NASDAQ CM: MBOT), a medical device company specializing in the design and development of transformationa
Read more →MBOTMicrobot Medical Moves to State-of-the-Art Facility to Meet Next Phase of the Company’s Development Efforts
HINGHAM, Mass., May 02, 2018 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ CM:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, relocated its global Research & Development facility to the Caesare
Read more →MBOTMicrobot Medical Exercises Option to Acquire Novel Technology from Cardiosert Ltd. Expands Intellectual Property (IP) Portfolio, Addressable Markets and Barriers of Entry Hingham, MA
Medical Exercises Option to Acquire Novel Technology from Cardiosert Ltd. Intellectual Property (IP) Portfolio, Addressable Markets and Barriers of Entry MA - April 16, 2018 - Microbot Medical Inc. (NASDAQ CM: MBOT), a medical device company specializing in the design and deve
Read more →MBOTMicrobot Medical's Self-Cleaning Shunt Awarded a Grant by the European Commission Non-Dilutive Grant Strengthens Balance Sheet for Further Milestone Achievements Hingham, MA
Medical's Self-Cleaning Shunt Awarded a Grant by the European Commission Grant Strengthens Balance Sheet for Further Milestone Achievements MA - April 12, 2018 - Microbot Medical Inc. (NASDAQ CM: MBOT), a medical device company specializing in the design and development of tra
Read more →MBOTMicrobot Medical Announces Appointment of Chief Technology Officer
HINGHAM, Mass., April 05, 2018 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced the appointment of Mr. Simon Sharon as Chief Technol
Read more →MBOTMicrobot Medical Announces Appointment of Chief Technology Officer Hingham, MA
Medical Announces Appointment of Chief Technology Officer MA - April 5, 2018 - Microbot Medical Inc. (NASDAQ CM: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced the appointment of
Read more →MBOTMicrobot Medical’s CEO to Speak as an Industry Expert at the YJP CEO Healthcare Symposium
HINGHAM, Mass., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that Harel Gadot, CEO, President and Chairman, will b
Read more →MBOTMicrobot Medical Inc. to Initiate Townhall Meetings Initial Event Planned for Thursday, February 1st at 4:30pm ET Hingham, MA
Medical Inc. to Initiate Townhall Meetings Event Planned for Thursday, February 1st at 4:30pm ET MA - January 31, 2018 - Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technolo
Read more →MBOTMicrobot Medical Enters into Agreement to Acquire Novel Technology to Enhance Existing Technology Platforms and Strengthen Patent Portfolio Hingham, MA
Medical Enters into Agreement to Acquire Novel Technology to Enhance Existing Technology Platforms and Strengthen Patent Portfolio MA - January 8, 2018 - Microbot Medical Inc. (NASDAQ CM: MBOT), a medical device company specializing in the design and development of transformati
Read more →MBOTMicrobot Receives Notice of Allowance for U.S. Patent Covering its TipCAT Technology Platform Hingham, MA
Receives Notice of Allowance for U.S. Patent Covering its TipCAT Technology Platform MA - December 14, 2017 - Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, tod
Read more →MBOTP. (Laxmin) Laxminarain Appointed to Microbot Medical's Board of Directors Medical Device Executive Broadens Strategic and Commercial Experience Hingham, MA
(Laxmin) Laxminarain Appointed to Microbot Medical's Board of Directors Device Executive Broadens Strategic and Commercial Experience MA - December 12, 2017 - Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transf
Read more →MBOTMicrobot Medical Inc. Receives Additional Government Grant for Development of its Self-Cleaning Shunt
HINGHAM, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, has been awarded an additional non-dilutive grant of up to 2,610,000
Read more →MBOTMicrobot Medical Inc. Receives Additional Government Grant for Development of its Self-Cleaning Shunt Hingham, MA
Medical Inc. Receives Additional Government Grant for Development of its Self-Cleaning Shunt MA - November 8, 2017 - Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologi
Read more →MBOTMicrobot Medical Inc. Expands Global IP Portfolio as Patent in India Covering the Company’s TipCAT™ Technology Platform is Issued
HINGHAM, Mass., Sept. 15, 2017 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that Intellectual Property India granted patent No.
Read more →MBOTMicrobot Medical Inc. Expands Global IP Portfolio as Patent in India Covering the Company's TipCAT Technology Platform is Issued Hingham, MA
Medical Inc. Expands Global IP Portfolio as Patent in India Covering the Company's TipCAT Technology Platform is Issued Hingham, MA - September 15, 2017 - Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transforma
Read more →MBOTMicrobot Medical Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference Hingham, MA
Medical Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference MA - September 7, 2017 - Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, toda
Read more →MBOTMicrobot Medical Inc. to Report Second Quarter Results on
Medical Inc. to Report Second Quarter Results on August 14, 2017 Call Scheduled for Monday, August 14th at 5:00pm ET MA - August 10, 2017 - Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robot
Read more →MBOTMicrobot Medical Inc. Reports Second Quarter 2017 Financial Results and Recent Development and Strategic Progress
HINGHAM, Mass., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today reported financial and operational results for the quarter and
Read more →MBOTMicrobot Medical Inc. Reports Second Quarter 2017 Financial Results and Recent Development and Strategic Progress Investor Update Conference Call today at 5:00pm ET Hingham, MA
Medical Inc. Reports Second Quarter 2017 Financial Results and Recent and Strategic Progress Update Conference Call today at 5:00pm ET MA - August 14, 2017 - Microbot Medical Inc. (NASDAQ CM: MBOT), a medical device company specializing in the design and development of transf
Read more →MBOTMicrobot Medical Inc. to Report Second Quarter Results on August 14, 2017
HINGHAM, Mass., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, will release second quarter 2017 financial and operational results on
Read more →MBOTMicrobot Medical Inc. Continues to Solidify IP Portfolio with US Patent for Previously Disclosed Device for Preventing Shunt Stenosis Hingham, MA
Medical Inc. Continues to Solidify IP Portfolio with US Patent for Previously Disclosed Device for Preventing Shunt Stenosis MA - June 14, 2017 - Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transformational mic
Read more →MBOTMicrobot Medical Announces Closing of $10 Million Registered Direct Offering of Common Stock Hingham, MA
Medical Announces Closing of $10 Million Registered Direct Offering of Common Stock MA - June 9, 2017 - Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, closed it
Read more →MBOTMicrobot Medical Announces $10 Million Registered Direct Offering of Common Stock Hingham, MA
Medical Announces $10 Million Registered Direct Offering of Common Stock MA - June 5, 2017 - Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, announced today that
Read more →MBOTMicrobot Medical Inc. Announces Issuance of a Canadian Patent Covering a Self-Cleaning Shunt Continues to Strengthen Global IP Portfolio for ViRob and TipCAT Technology Platforms Hingham, MA
Medical Inc. Announces Issuance of a Canadian Patent Covering a Self-Cleaning Shunt to Strengthen Global IP Portfolio for ViRob and TipCAT Technology Platforms MA - May 31, 2017 - Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and
Read more →MBOTMicrobot Medical Inc. Announces Issuance of a Canadian Patent Covering a Self-Cleaning Shunt
HINGHAM, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, announced today that the Canadian Intellectual Property Office has gra
Read more →MBOTMicrobot Medical Inc. Reports First Quarter 2017 Financial Results and Recent Development Progress
HINGHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today reported financial and operational results for the quarter ended
Read more →MBOTMicrobot Medical Inc. Reports First Quarter 2017 Financial Results and Recent Development Progress Hingham, MA
Medical Inc. Reports First Quarter 2017 Financial Results and Recent Development Progress MA - May 15, 2017 - Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, tod
Read more →MBOTMicrobot Medical Inc. Announces Investor Briefing Conference Call and Webcast
HINGHAM, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, announced today that it will host an investor briefing conference ca
Read more →MBOTFinal Microbot Medical Inc. Announces Investor Briefing Conference Call and Webcast Scheduled for Thursday, April 6 th at 10:00am ET Hingham, MA
Medical Inc. Announces Investor Briefing Conference Call and Webcast for Thursday, April 6th at 10:00am ET MA - March 29, 2017 - Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical
Read more →MBOTMicrobot Medical Inc. to Present at the 29th Annual ROTH Growth Conference
HINGHAM, Mass., March 13, 2017 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, is scheduled to present at the 29th Annual ROTH Conference on Wednes
Read more →MBOTMicrobot Medical Inc. To Ring Closing Bell at Nasdaq On February 23, 2017
HINGHAM, Mass., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NasdaqCM:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, announced the Company will ring the Nasdaq Closing Bell at the Nasd
Read more →MBOTMicrobot Medical Inc. Announces Significant Technology Patent Allowance in the U.S.
HINGHAM, Mass., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced the U.S. Patent and Trademark Office (USPTO) has issu
Read more →MBOTMicrobot Medical Inc. (Nasdaq: MBOT) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, will visit the Nasdaq MarketSite in Times Square. In honor of the occasio
Read more →MBOTRE: PATENT exhibit991.htm MICROBOT MEDICAL For Immediate Release Microbot Medical Inc. Announces Significant Technology Patent Allowance in the U.S. Hingham, MA
Microbot Medical Inc. Announces Significant Technology Patent Allowance in the U.S. Hingham, MA - February 22, 2017 - Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologi
Read more →MBOTMicrobot Medical Inc. Strengthens Board of Directors with Medical Device Veteran Martin J. Madden
HINGHAM, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced the appointment of Martin J. Madden, to the Company's
Read more →MBOThtm MICROBOT MEDICAL For Immediate Release Microbot Medical Inc. Strengthens Board of Directors with Medical Device Veteran Martin J. Madden Hingham, MA
Microbot Medical Inc. Strengthens Board of Directors with Medical Device Veteran Martin J. Madden Hingham, MA - February 7, 2017 - Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medic
Read more →MBOTMicrobot Medical Inc. Announces Research Collaboration Agreement with Washington University School of Medicine, a Leading Academic Institution to Evaluate a Revolutionary Self-Cleaning Shunt Device Designed to Prevent Ob
Microbot Medical Inc. Announces Research Collaboration Agreement with Washington University School of Medicine, a Leading Academic Institution to Evaluate a Revolutionary Self-Cleaning Shunt Device Designed to Prevent Obstruction in Cerebrospinal Fluid Catheters Studies to be A
Read more →MBOTMicrobot Medical Inc. to Present at the Thirteenth Annual Noble Capital Markets Investor Conference
HINGHAM, Mass., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, announced today that Harel Gadot, Chief Executive Officer, President,
Read more →MBOTMicrobot Medical Inc. Announces $3.5 Million Registered Direct Offering Net Proceeds to be Used to Continue Development of Micro-Robotics Technology Platforms Hingham, MA
Microbot Medical Inc. Announces $3.5 Million Registered Direct Offering Net Proceeds to be Used to Continue Development of Micro-Robotics Technology Platforms Hingham, MA January 5, 2017 Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the desig
Read more →MBOTINDEPENDENT AUDITORS REPORT TO THE SHAREHOLDERS OF MICROBOT MEDICAL LTD. We have audited the accompanying financial statements of Microbot Medical Ltd. ( the Company ), which comprise the balance sheets as of
INDEPENDENT AUDITORS REPORT TO THE SHAREHOLDERS OF MICROBOT MEDICAL LTD. audited the accompanying financial statements of Microbot Medical Ltd. ( the Company ), which comprise the balance sheets as of December 31, 2015 and 2014 and the related statement of operations, statement
Read more →MBOTMICROBOT POWERPOINT PRESENTATION exhibit99.htm TRANSFORMING MEDICAL TREATMENTS THROUGH MICRO-INVASIVE ROBOTICS Investor Presentation December 2016 NASDAQ:MBOT FORWARD LOOKING STATEMENTS THIS DOCUMENT IS PRIVATE AND CONFI
TRANSFORMING MEDICAL TREATMENTS THROUGH MICRO-INVASIVE ROBOTICS Investor Presentation December 2016 NASDAQ:MBOT FORWARD LOOKING STATEMENTS THIS DOCUMENT IS PRIVATE AND CONFIDENTIAL, CONTAINS SENSITIVE BUSINESS INFORMATION OF MICROBOT MEDICAL INC. ("MICROBOT") AND IS NOT FOR PUBL
Read more →MBOThtm Microbot Medical For Immediate Release Microbot Medical Inc. Announces First Investor Briefing Conference Call and Webcast Scheduled for Monday, December 19 th at 4:30pm ET Hingham, MA
Microbot Medical Inc. Announces First Investor Briefing Conference Call and Webcast Scheduled for Monday, December 19th at 4:30pm ET Hingham, MA - December 15, 2016 - Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of
Read more →MBOTMicrobot Medical Inc. Announces First Investor Briefing Conference Call and Webcast
HINGHAM, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, announced today that it will host its first investor briefing confere
Read more →MBOTMICROBOT PRESS RELEASE exhibit991.htm MICROBOT MEDICAL Microbot Medical Appoints Hezi Himelfarb as General Manager and Chief Operating Officer Seasoned Healthcare Executive Brings Broad Operational, Commercial and Capita
Microbot Medical Appoints Hezi Himelfarb as General Manager and Chief Operating Officer Seasoned Healthcare Executive Brings Broad Operational, Commercial and Capital Markets Experience Hingham, MA - December 6, 2016 - Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device c
Read more →MBOTMicrobot Medical Appoints Hezi Himelfarb as General Manager and Chief Operating Officer
HINGHAM, Mass., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that Mr. Hezi Himelfarb has been appointed General Ma
Read more →MBOTMicrobot Medical Closes Asset Sale; Proceeds will be Used to Further Develop its Innovative Micro-robotic Technologies Hingham, MA
Microbot Medical Closes Asset Sale; Proceeds will be Used to Further Develop its Innovative Micro-robotic Technologies Hingham, MA December 1, 2016 Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational mic
Read more →MBOTMicrobot Medical Closes Asset Sale; Proceeds will be Used to Further Develop its Innovative Micro-robotic Technologies
HINGHAM, Mass., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, closed the previously disclosed asset purchase agreement with BOCO Si
Read more →MBOTMicrobot Medical Closes Merger Transaction; Initiates Trading on NASDAQ as MBOT Innovative Company is Advancing Transformational Micro-Robotic Technologies to Treat and Diagnose Various Medical Conditions Hingham, MA
Microbot Medical Closes Merger Transaction; Initiates Trading on NASDAQ as MBOT Innovative Company is Advancing Transformational Micro-Robotic Technologies to Treat and Diagnose Various Medical Conditions Hingham, MA November 28, 2016 Microbot Medical Ltd., a medical device com
Read more →MBOTStemCells, Inc. and Microbot Medical Ltd. Announce Strategic Merger Companies Plan to Pursue Development of Robotics Based Medical Devices for the Treatment of Cerebrospinal Fluid and Gastrointestinal Disorders, as Well
StemCells, Inc. and Microbot Medical Ltd. Announce Strategic Merger Companies Plan to Pursue Development of Robotics Based Medical Devices for the Treatment of Cerebrospinal Fluid and Gastrointestinal Disorders, as Well as Other Conditions NEWARK, CA and Yokneam, Israel, Augus
Read more →MBOTImportant Information and Where to Find It This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. A definitive proxy state
Investor Presentation August 2016 Important Information and Where to Find It This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. A definitive proxy statement and a proxy card wi
Read more →MBOTSTEMCELLS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS NEWARK, Calif., (
STEMCELLS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS NEWARK, Calif., (March 8, 2016) StemCells, Inc. (NASDAQ: STEM) today announced that it intends to offer and sell common stock, Series A Warrants and Series B Warrants, subject to market and other co
Read more →MBOTSECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this Agreement ) is dated as of
SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this Agreement ) is dated as of July 14, 2014, between StemCells, Inc., a Delaware corporation (the Company ), and each purchaser identified on the signature pages hereto (each, including its successors and assig
Read more →MBOTPURCHASE AGREEMENT PURCHASE AGREEMENT (the Agreement ), dated as of
PURCHASE AGREEMENT (the Agreement ), dated as of June 3, 2013, by and between STEMCELLS, INC., a Delaware corporation, (the Company ), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the Subject to the terms and conditions set forth in this Agreement,
Read more →MBOTSTEMCELLS, INC. REPORTS FOURTH QUARTER AND YEAR END 2011 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE NEWARK, CA (
STEMCELLS, INC. REPORTS FOURTH QUARTER AND YEAR END 2011 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE NEWARK, CA (March 13, 2012) StemCells, Inc. (NASDAQ: STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in ste
Read more →MBOTRodney Young Chief Financial Officer (510) 456-4128 STEMCELLS
STEMCELLS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS NEWARK, Calif., December 15, 2011 StemCells, Inc. (NASDAQ: STEM) today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritt
Read more →MBOTRodney Young Chief Financial Officer (510) 456-4128 STEMCELLS, INC. PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2011
CONTACT: Rodney Young Chief Financial Officer (510) 456-4128 STEMCELLS, INC. PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2011 FINANCIAL RESULTS NEWARK, Calif., November 1, 2011 StemCells, Inc. (NASDAQ: STEM), a leading stem cell company developing and commercializi
Read more →MBOTRodney Young Chief Financial Officer (510) 456-4128 STEMCELLS, INC. REPORTS SECOND QUARTER FINANCIAL RESULTS NEWARK Calif.
CONTACT: Rodney Young Chief Financial Officer (510) 456-4128 STEMCELLS, INC. REPORTS SECOND QUARTER FINANCIAL RESULTS NEWARK Calif., July 28, 2011 StemCells, Inc. (NASDAQ: STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and
Read more →Competitive Position
How MBOT ranks across every disease it competes inCompetitive Position is a premium feature
See how MBOT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial